Main programme gapsummit 2018 digital

Programme

Challenge Grow Connect University of Cambridge, UK 16th — 18th April 2018

GapSummit 2018 Share your experience with #gapsummit2018 and connect with us on the social media below:

GlobalBiotechRevolution global-biotech-revolution @GlobalBRev globalbiotechrevolution.com gapsummit.com

Table of Contents Welcome 2 Overview and Mission of Global Biotech Revolution and GapSummit 2018

4

Overview of Gaps

6

Detailed Agenda

8

Workshop Topics

16

Profiles – Speakers

18

Profiles – 100 Leaders of Tomorrow

52

Voices of Tomorrow Competition

78

Profiles - Voices of Tomorrow Mentors

80

GapSummit 2018 Executive Committee

90

Global Biotech Revolution Executive Committee

92

Acknowledgements 96 Partners and Sponsors Venue Details

97 107

Map 108 Accommodation

109

Information 110 Cambridge Sights

112

Programme Overview

113

1

A note from the GapSummit 2018 Committee

2

Welcome to Global Biotech Revolution’s (GBR) international and intergenerational leadership summit in biotechnology.

The GapSummit conference will allow you to discuss the current challenges facing global biotechnology between now and 2050, and to ideate solutions to these.

Congratulations to our Leaders of Tomorrow on being selected through a highly competitive application pro-

­ess. You are joining us from over c forty nations across six continents.

We wish you the best as you embark upon an opportunity of a lifetime: debating and developing solutions to challenges in biotechnology with the Leaders of Today. We hope that the platform we are providing you with over the next few days will allow you to embody our core values: Challenge, Grow, Connect.

During the summit, make the most of the interaction opportunities provided

whilst reflecting on the change, action and impact you wish to bring throughout your own careers.

The team is thankful for the advice and support we have received from the GBR Executive Team, GapSummit Advisory Board, Speakers and Sponsors who have helped build the GapSummit 2018 into an intergenerational leadership forum for global biotechnology.

GapSummit 2018 Advisory Board

Sir Gregory Winter Advisory Board Chair, Master of Trinity College University of Cambridge

Prof Christopher M Dobson John Humphrey Plummer Prof of Chemical and Structural Biology Master of St John’s College University of Cambridge

Professor Chris Lowe Director, Cambridge Academy of Therapeutic Sciences (CATS), University of Cambridge

A note from Sir Gregory Winter

“ Biotechnology is about doing things in the real world, so many other skills are needed in addition to science and technology - including

3

Dr Menelas N Pangalos Executive Vice President, IMED Biotech Unit & Global Business Development, AstraZeneca

politics, management and business. It can take years to assemble these skills in individuals or teams, and it can take years for projects to come to fruition. It takes sustained energy to drive them. So I'm delighted at the focus of the conference on the young - they have both the energy and the time.”

Dr Jane Osbourn Vice-President R&D MedImmune

Overview and Mission of Global Biotech Revolution and GapSummit 2018

4

ŠChris Williamson

GBR is a student-led not-for-profit with the mission to inspire young people and support the next generation of leaders to ensure the sustainability and growth of the biotechnology industry. This is achieved through our three core values:

Grow To grow through acquiring knowledge, training, skills, and perspectives of young leaders. To inspire future leaders to grow their local bio-economies and look beyond to see the impact they can make globally

Challenge To challenge current knowledge, challenge industrial dogmas, challenge current leaders, and challenge each other

Connect To connect with leaders of today, connect with each other and inspire other students worldwide

We engage key stakeholders through conferences and online material to initiate and build global conversations and collaborations.

GBR’s flagship event is the GapSummit. It is the world's first global and inter-generational leadership summit in biotechnology, with the mission to inspire and engage the next generation of leaders.

Who Are The Leaders of Tomorrow?* Engineer 1% Consultant 2% Medical Doctor

2%

Entrepreneur 7% Pharma/Biotech 7% Undergraduate 13% PostDoc/Scientist 14% Postgraduate (PhD, MA, MBA)

47%

Other 7%

A growing

network of 483

Leaders of Tomorrow from 59 countries

*Data collected across previous years of GapSummit

5

Overview of the Gaps Digital Healthcare and Personalised Medicine Gap Novel technologies to advance digital health have created new avenues to monitor individual patients and to identify early symptoms of human diseases.

It is thus no surprise that established tech companies are currently expanding their focus on healthcare and biotech.

Digital Healthcare How can new digital health technologies be integrated into the current healthcare system?

How will digital technologies revolutionise healthcare?

6

ŠChris Williamson

How will the roles and responsibilities of the patient change?

The healthcare sector increasingly recognizes the advent of personalised or precision medicine (PM), in which genomics and other cutting-edge diagnostic tools are revolutionising targeted therapy. However, these advances have resulted in numerous challenges including physician education, patient responsibility, treatment costs, ethical dilemmas - and how PM will deal with the continuous accumulation of big data. The personalised medicine panel will discuss the major challenges in the field and how these can be overcome in the future.

Personalised Medicine What role will advances in genomics and diagnostics play in driving personalised medicine?

What are the risks of ever-growing patient information?

Road from Academia to Industry Gap Many young bio-entrepreneurs have a strong academic research background.

Often, these experiences heavily influence the identification of a gap in the market and the subsequent development of a new technology.

However, realising the translational potential of new discoveries provides a very different challenge to their scientific development.

Research pioneers, serial entrepreneurs and industry leaders with an academic background will provide insight into their experiences and give advice on translating your academic discoveries into a start-up.

How would you drive the early translational development of a novel application or technology that was conceived in an academic laboratory?

Sustainability Gap Food and energy supply for a growing population and climate change are key issues to be resolved in the very near future. Novel technologies and biotech ventures are a prerequisite to achieve global sustainability. We will focus on advances in agricultural biotechnology, particularly in developing countries, and how genetically modified crops are contributing to the advent of the second green revolution.

Over the past years, gene editing has also been applied to improve yields of food supply other than crops. Besides

the food industry, numerous biotech ventures are pioneering innovative solutions to develop biofuels, biomaterials and alternative energy sources to address the global energy crisis.

What role can biotechnology play in the attempt to solve these worldwide challenges?

Agritech What role can agritech play in the attempt to solve the global food crisis?

White biotechnology How can the industrial biotech sector be revolutionised to make our planet more sustainable in the future?

Drug Affordability Gap Drug pricing is a common debate in the pharmaceutical and biotech industry and has certainly contributed to the negative reputation of Big Pharma companies.

During the GapSummit 2018, we will discuss drug affordability and global accessibility. Many life-saving medicines are inaccessible for millions of patients across the world, and in particular across low-income countries. The aim of this debate will be to discuss the process of global drug pricing, the justification of treatment costs and the moral responsibility of the pharmaceutical industry to prioritise patients’ lives over stakeholder interests.

How does drug pricing need to change in the future to provide affordable life-saving drugs to patients across the world?

R&D Productivity Gap – How Industry Has To Innovate Over the past decade drug prices have continuously risen as a result of high failure rates during research & development of novel drugs. In order to improve efficiency of the pharmaceutical industry, R&D productivity has to significantly improve.

This revolution in R&D productivity is likely to demand novel models of industry innovation, which leading R&D executives from the pharmaceutical and biotech industry will discuss during the GapSummit.

How can biotech and pharmaceutical companies improve R&D productivity in the future?

Funding Gap This Gap will focus on the funding opportunities for young biotech start-ups. As a young bio-entrepreneur, raising funding throughout the early stages of the venture is a crucial yet daunting task. We will discuss sources of funding in the biotech industry and beyond. Funding experts will include angel investors, venture capitalists and corporate investors. The expert panel will not only include investors, but also biotech and pharma executives sharing their views on funding opportunities available to young start-ups.

As a young bio-entrepreneur, how do you convince an investor to support you?

Young Entrepreneurs Gap The GapSummit 2018 will welcome 100 Leaders of Tomorrow from across the world, who share a passion for biotechnology and wish to drive the global bio-economy in the future. Many of these young talents are aspiring biotech entrepreneurs and share a strong ambition to found an innovative start-up. During the GapSummit, young bio-entrepreneurs will share their experience of founding and developing a start-up venture. They will discuss their personal journeys with the 100 Leaders of Tomorrow.

How do I, as an ambitious entrepreneur, attract funding from investors?

How do I find the right people to develop my start-up?

7

Programme Day 0 15th April

Leaders of Tomorrow Welcome Day

14:00

Check-in at Pembroke or Sidney Sussex College from 12pm

15:30 – 16:15

Registration at Old Divinity School

16:15 – 16:30

Introductions

16:30 – 18:00

Welcome Sessions (3 x 30min rotations) I – Pitching Prof Alan Barrell, Entrepreneur in Residence, Judge Business School, University of Cambridge II – Ideation & Growing your Ecosystem Miranda Weston-Smith, Business Development Consultant, BioBeat Founder

8

III – Ice-breakers

18:00 – 19:00

Networking Drinks

Day 1 16th April 08:00 – 08:45

Registration and Breakfast

08:45 – 09:00

Welcome Felix Breyer, President, GapSummit 2018

09:00 – 10:00

Opening Keynote Speech Fighting Tomorrow’s Inequities: Innovation and the Future of Global Health Dr Trevor Mundel, President of Global Health, Bill & Melinda Gates Foundation

10:00 – 10:15

Personalised Medicine Anu Acharya, CEO, Mapmygenome

10:15 ­- 10:45

Refreshments

10:45 – 12:00

Personalised Medicine Gap Panel Discussion

Panel Chair: Prof Richard Barker, Founding Director, CASMI and New Medicine Partners Anu Acharya, CEO, Mapmygenome Dr Menelas N Pangalos, Executive Vice President, IMED Biotech Unit & Global Business Development, AstraZeneca Dr George Poste, Chief Scientist, Complex Adaptive Systems and Professor of Health Innovation, Arizona State University Dr Richard Klausner, Founder and Director, Juno Therapeutics and Grail 12:00 – 13:00

Lunch

13:00 – 13:15

Digital Health and its Impact on the Pharma Industry Dr Ameet Nathwani, Executive Vice President, Chief Medical Officer / Global Head of Medical Function, Sanofi

13:15 – 14:30

Digital Health Gap Panel Discussion Panel Chair: Dr Ameet Nathwani, Executive Vice President, Chief Medical Officer / Global Head of Medical Function, Sanofi Lucien Engelen, Director, REshape Center for Health(care) Innovation Dr Stephen Friend, Co-Founder of Sage Bionetworks, and 4YouandMe Dr Divya Dhar, CEO and Co-Founder, Swish Dr Kyu Rhee, Vice President and Chief Health Officer, IBM Corporation and IBM Watson Health

14:30 – 15:00

Refreshments

9

Programme Day 1 16th April 15:00 – 15:20

Exploring fundamental unknowns that prevent us from using our devices to navigate between disease and health Dr Stephen Friend, Co-Founder of Sage Bionetworks, and 4YouandMe

15:20 - 16:20

Keynote - R&D productivity in the big pharma industry Dr Göran Ando, Chairman, Novo Nordisk

16:20 - 16:50

Refreshments

16:50 – 18:00

Road from Academia to Industry Gap Panel Discussion

Panel Chair: Professor Chas Bountra, Professor of Translational Medicine,

10

Head of Structural Genomics Consortium, University of Oxford Sir Philip Cohen, Professor of Enzymology and Deputy Director of the Division of Signal Transduction Therapy, University of Dundee Dr Jane Osbourn, Vice-President R&D, MedImmune Prof Raymond F. Schinazi, Frances Winship Walters Professor of Pediatrics and Chemistry, Director of Laboratory of Biochemical Pharmacology, Emory University Prof Stephen Caddick, Director of Innovation, The Wellcome Trust Sir Gregory Winter, Master of Trinity College, University of Cambridge 18:00 – 18:30

Intermission

18:30 – 19:30

Drinks Reception at the Trinity College Masters Lodge Host: Sir Gregory Winter, Master of Trinity College

19:30 – 22:00

Gala Dinner in the Great Hall, Trinity College

Day 2 17th April 08:00 – 08:45

Breakfast

08:45 – 09:00

Science, Ideology and daily life: The case of innovation for Tropical Crops Prof Baron Marc Van Montagu, Emeritus Professor, Ghent University

09:00 – 10:00

Sustainability – Agritech Gap Panel Discussion Panel Chair: Dr Margaret Zeigler, Executive Director, Global Harvest Initiative Dr Geoffrey von Maltzahn, Partner, Flagship Pioneering Prof Baron Marc Van Montagu, Emeritus Professor, Ghent University Sir Peter Kendall, Chair, Agriculture & Horticulture Development Board Dr Stanley Hirsch, CEO, FuturaGene Group

10:00 - 10:45

Keynote Mr Fabrizio Hochschild, Assistant Secretary-General for Strategic Coordination, United Nations

10:45 – 11:15

Refreshments

11:15 – 12:15

Drug Affordability Gap Panel Discussion

Panel Chair: Dr Brindan Suresh, Partner, McKinsey & Company Dr Yusuf Hamied, Non-executive Chairman, Cipla Limited Dr William A Haseltine, Chair and President, ACCESS Health International Jennifer Lee, Director of Health Economics, Market Access, Reimbursement, Patient Advocacy and Government Affairs, Janssen UK Dr Jeanne Lambrew, Senior Fellow, The Century Foundation

11

Programme Day 2 17th April 12:15 – 12:30

Emerging opportunities for the biotech industry Dr William A Haseltine, Chair and President, ACCESS Health International

12:30 – 13:30

Lunch

13:30 – 14:30

Keynote - Innovate with Impact Dr Paul Stoffels, Executive Vice President and Chief Scientific Officer, Johnson & Johnson

14:30 – 15:00

Addressing the Innovation Challenge Dr Kemal Malik, Member of the Board of Management, Bayer AG

12

15:00 - 15:30

Refreshments

15:30 – 16:30

R&D Productivity Gap Panel Discussion

Panel Chair: Bernard Munos, Senior Fellow, FasterCures (Milken Institute) Melinda Richter, Global Head, Johnson & Johnson Innovation, JLABS Dr Jan van de Winkel, President and CEO, Genmab A/S Dr Kelvin Stott, Director of Portfolio Management, Novartis David Redfern, Chief Strategy Officer, GSK 16:30 – 16:45

Walk to Workshop venue

16:45 – 18:30

Workshop sessions Venue: Cambridge Union & Old Divinity School

18:30 – 19:30

Intermission

19:30 – 22:00

Networking event at the Museum of Archaeology and Anthropology, Cambridge

Day 3 18th April 08:00 – 08:45

Breakfast

08:45 – 09:45

Keynote - An Accidental Entrepreneur Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon Limited

09:45 - 10:15

Life as a CEO – Interview with Dr David Pyott Board Member of Philips, Alnylam and Biomarin; Philanthropist; Former Chairman of the Board and Chief Executive Officer, Allergan Hosted by Dr Matthias Evers, Senior Partner, McKinsey & Company

10:15 – 10:45

Refreshments

10:45 – 12:00

Funding Gap Panel Discussion

Panel Chair: Adina Mangubat, CEO and Co-founder, Spiral Genetics Dr Kevin Johnson, General Partner, Medicxi Kate Bingham, Managing Partner, SV Health Investors Dr Hermann Hauser, Co-Founder and Partner, Amadeus Capital Partners 12:00 – 13:00

Lunch

13:00 – 15:00

Voices of Tomorrow Competition Finals Chair: Melinda Richter, Global Head, Johnson & Johnson Innovation, JLABS

15:00 – 15:30

Refreshments

13

Programme Day 3 18th April 15:30 – 16:30

Young Entrepreneurs Gap Panel Discussion

Panel Chair: Matthew Scholz, CTO, Immusoft Corporation Adina Mangubat, CEO and Co-founder, Spiral Genetics Dr Vivian Chan, CEO & Co-Founder, Sparrho Dr Geoffrey von Maltzahn, Partner, Flagship Pioneering Dr Xavier Duportet, CEO, Eligo Bioscience; President, Hello Tomorrow 16:30 – 16:45

Wielding the power of the small – enzymes and microbes – to tackle the challenges laid out by the Sustainable Development Goals Dr Claus Stig Pedersen, Head of Corporate Sustainability & EMEA Public Affairs, Novozymes

16:45 – 17:00

Refreshments

17:00 – 18:00

Sustainability – White Biotech Gap

14

Panel Discussion

Panel Chair: Dr Claus Stig Pedersen, Head of Corporate Sustainability & EMEA Public Affairs, Novozymes Shrikumar Suryanarayan, Managing Director, Sea6 Energy PVT LTD Sandra Sassow, CEO and Co-Founder, SEaB Energy 18:00 – 18:15

Voices of Tomorrow Competition Winner Announcement Chair: Melinda Richter, Global Head, Johnson & Johnson Innovation, JLABS

18:15 – 18:30

Closing Speech and Concluding Remarks Daniel Bode, COO, GapSummit 2018 Anna Gould, President, Global Biotech Revolution

18:30 - 19:30

Celebratory Drinks Reception

19:30 – open

Social Evening

Day 4 19th April

Social Activities And Departures

By 09:30am

Vacate room

09:00 – 16:00

Store luggage at Old Divinity School

12:00 – 14:00

Punting

14:00 – 15:30

Lunch

16:00

Final Departure

15

©Chris Williamson

Workshop Topics Infrastructure for Innovation Hosted by Urvashi Prasad and Professor Chris Lowe

16

The workshop will compare and contrast the challenges and opportunities with respect to the infrastructure for innovation in life sciences between large emerging economies like India and China on the one hand, and the UK on the other. Governments in these emerging economies have taken several steps, including removal of regulatory barriers, increase in funding, investment in human capital etc. to develop their countries into global innovation hubs. The workshop will review the effectiveness of these measures as well as highlight the priorities for the future.

Digital Health Hosted by Sanofi (Dr Olivier Gien) Digital Technologies open a wide field of opportunities in Healthcare: the first digital therapeutics are being reviewed by regulators; machine learning algorithms surpass human beings for diagnosing some diseases; telehealth is becoming widely available and reimbursed…coupled with the great progress being made in understanding biology, technologies will lead to spectacular improvements in healthcare. From moonshots (as it was done for nuclear weapons testing) to low-hanging fruits; will we be able, one day, to replace physical clinical trials by modeling and

©Chris Williamson

simulation? This workshop’s objective is to leverage the delegates’ collective intelligence to classify different Digital Health opportunities according to their value and feasibility, and maybe, give you an idea for your next start-up company!

Creating disruptive new businesses in a 350-year old company. Are you curious?

Hosted by Merck KGaA (Dr Christoph Hüls) Innovation is driven by curiosity. At Merck, we are curious about innovative ideas that use cutting edge science and technology to challenge and

change the status quo. Join us for our interactive workshop where we will show participants how, for 350 years, Merck has been constantly creating disruptive new businesses. For the next 350 years to come, your ideas can encounter the ambition of Merck even more; in the workshop we will explore core mainstream assumptions behind some of the greatest needs of today and ask participants to question, challenge and break them, through novel science and technology. With the game changing ideas generated, we will discuss with participants how the multinational company Merck approaches the next steps to make these ideas reality.

Inspiring yourself and others - Becoming a scientific entrepreneur Hosted by McKinsey & Company This will be an interactive and energetic session exploring what our extensive research shows are some of the hallmarks of inspirational leaders across different fields of endeavour - including in science and business. What frequently defines distinctive leaders, is the realization that to be able to lead others, they must first "lead self", unlocking the strengths and deep passions that can form the basis of their success.

During this workshop, we will spend time exploring this connection, along with sharing what we believe are the fundamental aspects of becoming a truly effective scientific entrepreneur and leader. #ScienceLeadership #ScientificEntrepreneur #InspirationalLeader #WinningWithTalent

©Chris Williamson

Diversity and Inclusion in Innovation Hosted by Johnson & Johnson Innovation (Madelaine Holden) At Johnson & Johnson, diversity is about your unique perspective. Inclusion is about creating a deep sense of belonging. It’s about you, your colleagues and the world we care for—all backgrounds, beliefs and the entire range of human experience— coming together. In the workshop we will explore some of the biggest barriers to creating a workplace that encompasses these principles and ask participants to find solutions to overcome these roadblocks that can stifle productivity and innovation.

‘How do we sustainably provide sufficient food for a growing population?’

Hosted by Bayer AG (Dr Oliver Martin)

The workshop will aim to develop recommendations for governments, businesses and civil society on how to transform agriculture for healthy people and planet. Participants will look at the future challenges from different lenses: 1) Innovation: How Life Science & Data/Engineering technologies will aid in transforming agriculture and enhance sustainability.

2) Business: Development of new business models. 3) Sustainability: The role of the environment & social inclusion in achieving the goal of sustainable food supply for a growing population.

Business Development as a Tool to Advance Your Start-Up Hosted by Molly Pyott and Professor Raymond Schinazi Workshop attendees will gain valuable insights into developing successful start-up biotech ventures. Emory University researcher and prolific biotech entrepreneur Raymond Schinazi and trade association business development executive Molly Pyott, will explore key topics including: how to build your network early in your career, select the right leadership and staff, attract investors, and choose partners, anchored on a thorough assessment of the technology’s competitive landscape.

17

Keynote Speakers Dr Gรถran Ando Chairman, Novo Nordisk

18

Gรถran Ando, MD, was CEO of Celltech Group plc, UK, until 2004. He joined Celltech from Pharmacia, now Pfizer, US, where he was executive vice president and president of R&D with additional responsibilities for manufacturing, IT, business development and Mergers & Acquisitions (M&A) from 1995 to 2003. From 1989 to 1995, Dr Ando was medical director, moving to deputy R&D director and then R&D director of Glaxo Group, UK. He was also a member of the Glaxo Group Executive Committee.

Dr Ando is a specialist in general medicine and a founding fellow of the American College of Rheumatology in the US. Dr Ando serves as chairman of the board of Symphogen A/S, Denmark and as a board member of Novo A/S, Denmark, Molecular Partners AG, Switzerland, EUSA Pharma Ltd., UK, and ICMEC, US. Dr Ando also serves as a Senior Advisor to Essex Woodlands Health Ventures Ltd., UK.

Dr Ando qualified as a medical doctor at Linkรถping Medical University, Sweden, in 1973 and as a specialist in general medicine at the same institution in 1978.

Dr Ando was first elected to the Board of Novo Nordisk A/S in 2005 and has been re-elected several times, most recently in 2017. Dr Ando became vice chairman of the Novo Nordisk A/S Board in 2006 and chairman in 2013. His term as a board member expires in March 2018.

Dr Ando became chairman of the Nomination Committee at Novo Nordisk A/S in April 2013 and chairman of the Research & Development Committee at Novo Nordisk A/S in March 2017.

In January 2017, the Board of Directors assessed that the special competences possessed by Dr Ando that are important for the performance of his duties are his medical qualifications and extensive executive background within the international pharmaceutical industry.

Mr. Fabrizio Hochschild of Chile is Assistant Secretary-General for Strategic Coordination in the Executive Office of the Secretary-General of the United Nations.

Reporting to the Chef de Cabinet, Mr. Hochschild works closely with other members of the Executive Office team to support the Secretary-General in ensuring coherence across the political, peacekeeping, development, humanitarian, human rights and rule-of-law portfolios. Prior to his appointment as Assistant Secretary-General, Mr. Hochschild served as Deputy Special Representative for the United Nations Multidimensional Integrated Stabilization Mission in the Central African Republic (MINUSCA), from July 2016.

He previously served as Deputy to the Secretary-General’s Special Adviser for the Summit on Addressing Large Movements of Refugees and Migrants.

Between 2013 and 2016, he served as United Nations Resident Coordinator, Humanitarian Coordinator and Resident Representative of the United Nations Development Programme (UNDP) in Colombia. He was the

Director of the Field Personnel Division within the Department of Field Support in New York from 2010 to 2012, and Chief of Field Operations and Technical Cooperation in the Office of the United Nations High Commissioner for Human Rights (OHCHR) in Geneva from 2005 until 2009.

Having begun his United Nations career in 1988 with the Office of the United Nations High Commissioner for Refugees (UNHCR) in Sudan, Mr. Hochschild served in subsequent postings with UNHCR, the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), the Office for the Coordination of Humanitarian Affairs and in peacekeeping.

Mr. Hochschild’s other assignments included postings to Jerusalem (19901991), Bosnia and Herzegovina (19911992), Geneva (1993-1996), New York (1998-1999), Timor-Leste (2000), Serbia (2001-2003) and the United Republic of Tanzania (2003-2005). He is a graduate of the University of Oxford in the United Kingdom. Born in 1963, he is married and has three children.

Mr. Fabrizio Hochschild Assistant Secretary-General for Strategic Coordination, United Nations

19

Keynote Speakers Kiran Mazumdar-Shaw Chairperson & Managing Director, Biocon Limited

20

A pioneer of the biotechnology industry in India and the head of the country’s leading biotechnology enterprise, Biocon, Ms. Kiran Mazumdar-Shaw is a highly respected businesswoman. Ms. Mazumdar-Shaw, a first generation entrepreneur, has made her country proud with a globally recognized biopharmaceutical enterprise that is committed to innovation and affordability in delivering world-class therapeutics to patients globally.

Named among TIME magazine’s 100 most influential people in the world, she is recognized as a global thought leader for Biotechnology. Under her stewardship, Biocon has evolved since its inception in 1978 from an industrial enzymes company to a fully-integrated, innovation-led, emerging global biopharmaceutical enterprise committed to reduce therapy costs of chronic conditions like diabetes, cancer and autoimmune diseases.

As a global influencer, she is ranked among Fierce Biotech’s list of the ‘World’s 25 Most Influential People in Biopharma,’ Forbes’ ‘100 Most Powerful Women’ and Fortune’s ‘Top 25 Most Powerful Women in Asia-Pacific.’ Recently, she was featured in 'The Worldview 100' listing of Biotech Visionaries in the prestigious US-based Scientific American magazine. She was also ranked second in the Global Medicine Maker Power List 2015, a top UK-based medical publication. U.S.-based Chemical Heritage Foundation conferred her with the ‘2014 Othmer Gold Medal’ and Germany-based Kiel Institute for the World Economy awarded her its coveted ‘2014 Global Economy Prize’ for the US based Business Foreign Policy magazine has named her among the ‘100 Leading Global Thinkers of 2014’.

Importantly, she has been recognized with the Padma Shri (1989) & the Padma Bhushan (2005), two of India’s prestigious civilian honors.

President of Global Health at the Bill & Melinda Gates Foundation, where we work to help all people lead healthy, productive lives. Science is my passion, and I believe data is key to making meaningful progress against factors causing human disease.

Global Health leads the foundation’s efforts in research and development of vaccines, drugs, and diagnostics to address major global health challenges in the developing world. We also oversee the foundation’s strategies in HIV, tuberculosis, malaria, pneumonia, diarrheal disease, enteric and diarrheal diseases, and neglected infectious diseases. We work on

platform technologies to accelerate development of global health solutions as well. All of this work occurs in collaboration with an international network of grantees and partners.

Dr Trevor Mundel President of Global Health, Bill and Melinda Gates Foundation

I joined the foundation in 2011 after holding a variety of roles in pharmaceutical development at Novartis, Pfizer and Parke-Davis. I am a native of South Africa, where I earned bachelor’s and medical degrees from the University of the Witwatersrand in Johannesburg. I also studied philosophy as a Rhodes Scholar at the University of Oxford before earning a Ph.D. in mathematics at the University of Chicago.

21

As Executive Vice President, Chief Scientific Officer, Johnson & Johnson, Paul Stoffels works with leaders across the organization to set the company-wide innovation agenda.

He is a member of the Johnson & Johnson Executive Committee and chairs the Johnson & Johnson R&D Management Committee.

Paul spearheads the Johnson & Johnson innovation pipeline by leading teams across the pharmaceutical, medical devices and consumer segments to discover and develop transformational healthcare solutions. He also steers Johnson & Johnson’s global public health strategy to make innovative

medicines and technologies accessible in resource-poor settings.

Paul’s visionary leadership was instrumental in the launch of Johnson & Johnson Innovation in 2013, which he now leads to fuel innovative science and technology through strategic partnerships, licensing and acquisitions. Paul also oversees JJDC, the oldest corporate venture fund in the life science industry.

In addition, Paul has responsibility for safety of all products of the Johnson & Johnson Family of Companies worldwide.

Dr Paul Stoffels Executive Vice President and Chief Scientific Officer, Johnson & Johnson

Speakers Anu Acharya CEO, Mapmygenome

Anu is the CEO at www.mapmygenome. in, a molecular diagnostics company to make people proactive about their health. Mapmygenome's products include prognostics and diagnostics tests. The prognostics range of products includes Genomepatri, Slimgene, Sugargene, Genomepatri Lite etc. The diagnostics products include BabyMap- carrier screening and Newborn Screening, Sma-RT kit series, SpoligoTB, single gene conditions, Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), Cardiac and Oncology panels including BRCA tests. All tests include Genetic Counseling.

Anu is the Founder and was the CEO of Ocimum Biosolutions from 2000 to 2013. Ocimum combines its Bioinformatics products, reference databases, data generation and data analytics on "big data" using LIMS backbone through its proprietary platform called RaaS.

Richard is an internationally respected leader in healthcare and life sciences.

US-based bio-therapeutics company.

She was named a "Young Global Leader" by the WEF for its class of 2011 and served on the WEF's Global Agenda Council of Personalised and Precision Medicine.

Anu loves to write on genomics, science and poetry.

22

Professor Richard W. Barker Founding Director, CASMI and New Medicine Partners

He is Founding Director of New Medicine Partners, a global firm assisting public and private sector organisations to accelerate the development and adoption of precision medicine. He also founded the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), a major UK academic initiative aimed at bringing biomedical advances more rapidly and affordably to patients.

He is chairman of the South London Health Innovation Network and of the corresponding Genomic Medicine Centre. He also chairs Image Analysis, a UK company using MRI to quantify the impact of therapy on disease and is a board member of Celgene, a major

His 30-year business career in healthcare has spanned biopharmaceuticals, diagnostics and medical informatics – both in the USA and Europe. The senior roles he has held include: Director General of the Association of the British Pharmaceutical Industry, General Manager of Healthcare Solutions for IBM, Chief Executive of Chiron Diagnostics and head of McKinsey’s European healthcare practice.

His book on the future of healthcare ‘2030 - The Future of Medicine: Avoiding a Medical Meltdown’ and his second book ‘Bioscience – lost in translation?’ are published by Oxford University Press.

Kate Bingham joined SVLS in 1991.

Kate currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. She has been responsible for past investments in Alantos, Auxilium, ESBATech, EUSA, Hexagen, Kinetix, KuDOS, Leukosite, Mednova, Micromet, PowderMed, RespiVert and current investments including Autifony, Bicycle, Convergence,

Pulmocide, Oncoethix,TopiVert and VHSquared. Prior to joining SVLS, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm. Kate has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with a MBA.

Kate Bingham Managing Partner, SV Health Investors

Chas is Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at Imperial College, London. Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.

antagonists are anti-emetic in preclinical and clinical studies.

Professor Chas Bountra Professor of Translational Medicine, Head of Structural Genomics Consortium, Oxford University

Prior to coming back to Oxford, Chas was Vice President and Head of Biology at GlaxoSmithKline. He was involved in the identification of more than 40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. More than 20 of these molecules progressed into patient studies and more than five of these delivered successful “Proof of Concept” data and hence progressed into late stage development. He was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron) and was the first to show that neurokinin NK1

His current interests are i) using X ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients, pre-competitively ii) focussing on epigenetic and genetically identified proteins, because these are likely to represent better targets for drug discovery, for many cancer, inflammatory, metabolic and neuro-psychiatric diseases iii) working with colleagues in Oxford to build major programmes in rare diseases and in Alzheimers Disease, and creating a “BioEscalator” for the rapid translation of SGC science and iv) building stronger links with local hospitals, patient groups, regulatory agencies, private investors, CROs, biotechs and large pharma companies, to create a new, more efficient ecosystem for pioneer drug discovery. (continued)

23

Speakers Chas believes the SGC has become a leader in human protein structural biology and epigenetics chemical biology, and is arguably one of the most successful open innovation, public – private partnerships in the world. Furthermore, with the many recent local developments (Target Discovery Institute, Kennedy Institute,

Dementia Institute), he believes Oxford is emerging as one of the major academic drug discovery centres in Europe.

Professor Stephen Caddick Director of Innovation, The Wellcome Trust

Stephen Caddick joined the Wellcome Trust in June 2015 and leads the Innovations division. Previously, he was Vice Provost (Enterprise & London) and Vernon Professor of Organic Chemistry and Chemical Biology at University College London. Stephen is a member of the London Local Enterprise Panel and the Scientific Advisory Board for MRC Technology, and Chair of the League of European Research Universities (LERU) Enterprise

and Innovation Community. He is co-founder of Synthetic Pages, an open access website, and Thiologics, an antibody-drug conjugate (ADC) biotech spin-out company. His laboratory focuses on chemical modification of proteins and antibodies for development of therapeutics and diagnostics. He has played an important role in the development of the chemical biology strategy and facilities within the Francis Crick Institute.

Dr Vivian Chan CEO & Co-Founder, Sparrho

Dr. Vivian Chan is CEO & Co-Founder of Sparrho, a London-based startup blending expert curation and machine learning to democratise science. Users from over 150 countries use Sparrho to stay on top of the research that matters to them from over 45,000 sources daily. Vivian has twice been invited to address EU ministers about the importance of open data for innovation, and was selected by MIT Technology Review as one of their 35

Innovators Under 35 in 2017, and by Management Today as one of their 35 Women Under 35 in 2015. Vivian completed her PhD in Biochemistry at the University of Cambridge, after spending a year working in a venture fund in Australia. Vivian is a former President & Chairman of Cambridge University Technology Enterprise Club (CUTEC), and was part of the inaugural Entrepreneur First cohort in 2012.

24

He has given over 300 invited lectures.

In 2012 he was voted one of the “top innovators in the industry”

Philip is a distinguished pioneer in studying the process of protein phosphorylation.

Philip received his B.Sc (1966) and Ph.D (1969) from University College London and then spent two years as a postdoctoral fellow at the University of Washington, Seattle, USA with Edmond Fischer (the 1992 Nobel Laureate for Medicine or Physiology).

In 1971 Philip returned to the UK to become a Faculty member at the University of Dundee, where he has worked ever since. Philip was a Royal Society Research Professor from 1984 to 2010, Director of the MRC PPU from 1990 to 2012 and Director of the SCottish Institute for ceLL Signalling (SCILLS) from 2008 to 2012. Philip was the Co-Director from 1998 to 2012 of the Division of Signal Transduction Therapy (DSTT), at that time Europe's

Divya Dhar is CEO and co-founder of Swish. A direct to consumer app that makes personalised recommendations for your skin care regimen. She’s previously built and sold Seratis, a care coordination software for hospitals. She also founded P3 Foundation, a non-profit, in its 8th year running whose aim is to inspire young people to end extreme poverty in the Asia

largest collaboration between a basic research institution and the pharmaceutical industry, and has been Deputy Director since 2012. According to Thomson Scientific, Philadelphia, Philip was the world’s second most cited scientist in the field of biology and biochemistry from 1992-2003, and the world’s most cited biochemist from 1999-2009. Philip has received an extensive list of awards and honours from around the world, ranging from the Colworth Medal (1977), membership of EMBO (1982), fellowship of the Royal Society of Edinburgh and the Royal Society of London (1984), Knight Bachelor in the Queen’s Birthday Honours list (1998), Foreign Associate of the National Academy of Science (2008), the MRC Millennium Medal (2013) and the Albert Einstein World Award of Science (2014).

Sir Philip Cohen Professor of Enzymology and Deputy Director of the Division of Signal Transduction Therapy, University of Dundee

Pacific region. Divya is an MD from the University of Auckland, having practiced for a few years. She then went on to complete a joint MBA/MPA degree program at Wharton Business School and Harvard Kennedy School respectively. Divya’s won numerous awards such as MedTech’s 40 Under 40 and Young New Zealander of the Year.

Dr Divya Dhar CEO and Co-founder, Swish

25

Speakers Dr Xavier Duportet CEO, Eligo Bioscience; President, Hello Tomorrow

Xavier Duportet, 29, is a genome architect. He cofounded Eligo Bioscience in 2014, while doing his PhD in Synthetic Biology at MIT and INRIA. He raised $24M from Khosla Ventures and Seventure to develop a new generation of ultra-precise biotherapeutics to battle antibiotic-resistant bacteria and sculpt our microbiome using genetic engineering and CRISPR/Cas9.

He is an MIT TR35 and was elected French Innovator of the year by the MIT Technology Review in 2015. He was recently awarded French PhD-Entrepreneur of the year by the Foundation

Norbert Segard, as one of the 40 under 40 Young Leaders in Europe, one of the 30 Under 30 by Forbes in 2017 and recently elected as a Technology Pioneer 2017 by the World Economic Forum. Xavier is also the founder and president of Hello Tomorrow, a global non-profit organization, operating in 45 countries, which goal is to accelerate the development of deeptech startups that transform disruptive scientific technologies into products or services to solve societal and industrial challenges.

Lucien Engelen Director REshape Center for Health(care) Innovation

It is at the intersection of technology and patient empowerment, which is where Lucien Engelen (1962), founding director of the Radboud University Medical Centre REshape Center and advisor to the Board of Directors (since 2007) feels most at home.

in the Nordics his modus operandi is always challenging, sometimes provocative but always techno-realistic.

26

The two worlds combined into the Radboud University Nijmegen Medical Centre and Singularity University in Silicon Valley & the Netherlands and

The objective is to keep Radboud University Nijmegen Medical Centre at the forefront of innovation and to have a soft landing in the future meanwhile creating a sustainable global health(care) for all. Creating breakthrough programs, foresights, and products if industry lacks progression itself.

Dr. Matthias Evers is a Senior Partner in McKinsey’s Hamburg office and co-leader of the EMEA Pharmaceuticals and Medical Products (PMP) R&D and Medical Practice. Since joining the firm in 2002, Matthias engaged with pharmaceuticals clients in EU but also in the US and in Asia transforming R&D organisations to overcome innovation and productivity issues through deep-rooted transformatory approaches; especially with focus on critical junctures and capabilities in early clinical development and in the late-stage clinical, medical, and commercialization space. In addition, he has engaged in translating

learnings between innovator and generics R&D (e.g. on biosimilars) as well as supporting a cross-industry dialog on drug innovation in multiple settings in Europe and the U.S.

Dr Matthias Evers Senior Partner, McKinsey & Company

Matthias holds a Ph.D. in Chemistry/ Biochemistry from the University of Bochum with a particular focus on Neuroscience. Before his career with McKinsey, he worked as a Research Associate and Postdoctorate at a Center for Molecular Neurobiology in Hamburg. He authored several articles in the field of bioinformatics and molecular biology.

27

Dr. Friend is the Co-Founder and Past-President of Sage Bionetworks, a non-profit organization that provides the tools and environment to conduct dynamic, large-scale collaborative biomedical research. Dr. Friend is also Co-Founder of 4YouandMe. He is an authority in the field of cancer biology and a pioneer in the field of the genetics of gene expression, integrating system biology approaches to complex diseases.

Dr. Friend co-founded Sage Bionetworks in 2009 on the belief that successful biomedical research requires the active participation of all stakeholders. Through Sage Bionetworks, he has worked to reimagine the role of citizens in the research process and to build the tools to empower citizens to contribute both their data and expertise as they see fit.

Under his leadership, Sage Bionetworks

has developed an open-source technology platform, called Synapse, for data-intensive analysis, sharing and reuse, enabling researchers to perform cutting edge computational biology and research by iteratively generating and testing novel hypotheses transparently and collaboratively. Sage Bionetworks has engaged the community to crowdsource solutions to complex biomedical questions through targeted DREAM challenges, and has expanded efforts in patient centered research through its mobile health initiatives.

From 2015 - 2017 he was a member of the Health Special Projects Team at Apple. He is now interested in how devices can nurture the desires of individuals to navigate towards health by asking fundamental questions

Dr Stephen Friend, Co-Founder of Sage Bionetworks, and 4YouandMe

Speakers about how to do individual assessments and how to provide them in ways that allow one to act on these suggestions. Prior to co-founding and leading Sage as President, Dr. Friend was Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck’s Basic Cancer Research efforts. Formerly Dr. Friend along with Dr. Hartwell founded and co-led the Fred Hutchinson Cancer

Research Center’s “Seattle Project”, an advanced institute for drug discovery and later they co-founded Rosetta Inpharmatics with Drs Hartwell and Hood.

Dr. Friend also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his M.D/Ph.D. from Indiana University.

Dr. Friend was named an Ashoka Fellow for his work at Sage Bionetworks.

Dr Olivier Gien Vice President, Global Head of Medical IT, Sanofi

Olivier Gien is Vice President, Global Head of Medical IT at Sanofi. Based in Paris, he holds a PhD in Artificial Intelligence applied to Organic Chemistry.

Dr. Gien has held several leadership positions at Sanofi, where he has led

globally Discovery Research Information Technologies then Clinical Development Information Technologies before taking his new role as Global Head of Medical IT in 2017.

Dr Yusuf Hamied Non-Executive Chairman, Cipla Ltd.

The pharmaceutical chemist, philanthropist and businessman, Dr. Y. K. Hamied, was born in Lithuania on July 25, 1936. As Non-Executive Chairman of Cipla Ltd., Dr. Hamied represents the second generation of Cipla’s founding family. Dr. Hamied obtained his Ph.D. in organic chemistry in 1960 from the University of Cambridge under the tutelage of the Nobel laureate Lord Alexander Todd. He joined Cipla in the same year as an R&D Officer. Dr. Hamied was appointed Managing Director of Cipla in 1976 and became Chairman of Cipla in

1989. He retired as Managing Director on 31 March, 2013 and has continued to be the Chairman in a non-executive role since 1 April, 2013.

28

For close to 60 years, Dr. Hamied has been an insightful R&D leader, a courageous industry captain, and an outspoken statesman of global pharma.

From affordable drugs in HIV to enabling one of the world’s largest portfolio of drugs and devices in inhalation therapy, his pioneering work and immense contribution to healthcare have been

celebrated around the world. In India, he was among the earliest supporters of a close relationship between the industry and the institutes of scientific excellence such as the Regional Research Laboratories (RRLs) and the Central Drug Research Institute (CDRI). Dr. Hamied was an early champion of palliative care in India, setting up the Cipla Palliative Care and Training Centre near Mumbai in 1997. In spearheading the manufacture of bulk drugs from the early 1960s, in combining three AIDS drugs into one in 2001, in creating a generic version of the prevailing innovator drug during the worldwide bird flu pandemic in 2005, Dr. Y.K. Hamied has always led scientific innovation and research from the front, with a steadfast humanitarian concern at the heart of his work.

For his distinguished service to the pharmaceutical industry, in 2005, Dr. Hamied

William A. Haseltine PhD has an active career in both science and business. He was a professor at Harvard Medical School and Harvard School of Public Health from 1976-1993 where he was Founder and the Chair of two academic research departments. He is well known for his pioneering work on cancer, HIV/AIDS and genomics. He has authored more than 200 manuscripts in peer-reviewed journals and is the author of several books. He is the Founder of Human Genome Sciences, Inc and served as the Chairman and

was awarded the Padma Bhushan by the Government of India, its third-highest civilian award. In 2013, Dr. Hamied was named by New Delhi Television (NDTV) as one of India’s 25 Greatest Global Living Legends. In 2014, the University of Cambridge awarded him an Honorary Doctorate, the highest honour that the University bestows, and in 2017, the Indian Institute of Technology Bombay (IIT-B), also awarded him an Honorary Doctorate. 2017 also saw Dr. Hamied receive the Public Health Hero award from Columbia University Mailman School of Public Health, and the firstever Scientists of Valor Award from the International Society of Travel Medicine (ISTM) Foundation. Dr. Hamied has been the recipient of several lifetime achievement awards, he is an Honorary Fellow of the Royal Society of Chemistry, and is a frequent presence on high-level international panels on healthcare.

CEO of the Company until 2004. He is also the Founder of several other successful biotechnology companies.

Companies he has founded account for five drugs currently on the market including Benlysta and ABTRAX (Human Genome Sciences,Inc), Velcade (Proscript/Leucocyte,Inc), and Provenge (Dendreon,Inc).

William Haseltine is currently Chairman and President of ACCESS Health International, Inc (www. accessh.org) that supports access to

29

Dr William A Haseltine Chair and President, ACCESS Health International

Speakers affordable, high quality health services in low, middle and high income countries, and Chairman Haseltine Foundation for Science and the Arts that fosters a dialog between sciences and the arts. He is an advisor to several governments, biotechnology and pharmaceutical companies.

He is a member of the Advisory Board of the IE University, Madrid, the Advisory Council for the Koch Institute of MIT and the Life Sciences Foundation, a member of the Advisory Boards of the Ragon Institute, The Rockefeller University Council, and The FXB Center for Health and Human Rights at the Harvard School of Public health. He is a Lifetime Governor of

30

Dr Hermann Hauser Co-Founder and Partner, Amadeus Capital Partners

Hermann co-founded Amadeus Capital Partners in 1997 with Anne Glover and Peter Wynn. In his long and successful history as an entrepreneur and venture capitalist, Hermann has founded or co-founded companies in a wide range of technology sectors.

These include Acorn Computers (where he helped spin out ARM), Active Book Company, Virata, Net Products, NetChannel and Cambridge Network Limited. He was a founder director of IQ (Bio), IXI Limited, Vocalis, SynGenix, Advanced Displays Limited (acquired by Cambridge Display Technology), Electronic Share Information Limited, E*Trade UK and has supported many other start-ups.

the New York Academy of Sciences and a member of the Board of AID for AIDS International. He is an honorary member of the Board of Trustees of the Brookings Institution, a member of the Council on Foreign Relations, a member of the Advisory Board of the Metropolitan Opera, New York, a member of the Chairman’s Council of the Metropolitan Museum, New York, a Member of the International Council of the Guggenheim Museum, The International Council of The Tate Modern, a Member of Board of Directors of the Young Concert Artists, Inc. and the Youth Orchestra of the Americas, The American Friends of the Budapest Orchestra, and the China Arts Foundation.

Hermann’s successes at Amadeus include: CSR plc (LON: CSR); Entropic Research Laboratory (acquired by Microsoft in 1999); Solexa (acquired by Illumina in 2007); and Icera (acquired

by Nvidia in 2011). He is currently a non-executive director of XMOS, a company that is revolutionising re-configurable silicon chips; Plastic Logic, the first company to commercialize flexible plastic transistors (currently used in computer displays); and Cambridge Broadband Networks, a leader in point-to-multipoint wireless backhaul products.

Hermann holds an MA in Physics from Vienna University and a PhD in Physics

from the University of Cambridge. He is a Fellow of the Institute of Physics and of the Royal Academy of Engineering, and an Honorary Fellow of King’s College, Cambridge. Hermann holds honorary doctorates from the Universities of Bath, Loughborough and from Anglia Ruskin University and was awarded an Honorary CBE for ‘innovative service to the UK enterprise sector’ in 2001. In 2004, he was made a member of the Government’s Council for Science & Technology. In

2012 he became a Fellow of the Royal Society in recognition of his contribution to the translation of science into business, in 2013 a Distinguished Fellow of BCS, the Chartered Institute for IT, and in 2015 an Honorary Knight Commander of the Most Excellent Order of the British Empire (KBE) for services to engineering and industry.

Dr. Stanley Hirsch is the Group CEO of FuturaGene Ltd. FuturaGene is a pioneer in plant genetic research and development for the global forestry, biopower and biofuel markets. FuturaGene’s key crops are eucalyptus, desert species and poplar. Its most advanced technologies are for yield improvement in sustainable industrial forestry. In April 2015, FuturaGene became the first company in the world to obtain regulatory approval to commercially deploy a yield enhanced genetically modified eucalyptus variety. Since July 2010, FuturaGene has been a wholly owned subsidiary of Suzano Pulp and Paper of Brazil. Prior to joining FuturaGene, Dr. Hirsch served as general manager of two diagnostics development companies and a drug development company.

Previously, he was also responsible for business development for a privately held group of healthcare companies,

where he oversaw the structuring and managing of joint ventures, startup companies, technology licensing and new product acquisitions. Early in his career, Dr. Hirsch was involved in the development of automated systems for plant tissue culture and he is a co-inventor of patents in plant biotechnology and micropropagation systems. Dr. Hirsch serves as Chairman at Foamix Pharmaceuticals, a NASDAQ-traded specialty pharmaceutical company (NASDAQ:FOMX) and at One World Cannabis (OTCQB:OWCP), which is developing cannabis-based pharmaceuticals and is a Board Director at Biological Industries, a research products company and has advised various venture capital funds. He received his D. Phil. from Oxford University in Cell Biology and Immunology and his B.SC and B.Sc. (Med) Honours from the University of Cape Town.

Austrian by birth, Hermann speaks German, English and conversational Italian and French.

Dr Stanley Hirsch CEO, FuturaGene Group

31

Speakers Madelaine Holden Innovation Activation Manager, Johnson & Johnson Innovation, JLABS

Madelaine is the Innovation Activation Manager for EMEA at Johnson & Johnson Innovation, JLABS. She is responsible for marketing campaigns and external engagement activations within the EMEA region, including initiatives led by the London Innovation Centre. In this role, Madelaine oversees strategic planning and coordination, working closely with the whole Innovation Activation team.

She curates and implements a cutting edge curriculum that catalyzes the innovation ecosystem and promotes

Johnson & Johnson Innovation and JLABS core capabilities.

Dr Kevin Johnson General Partner, Medicxi

Prior to co-founding Medicxi, Kevin was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003. Kevin spearheaded Index’s very first experimental asset-centric investment, in PanGenetics, which was later acquired

by Abbott Pharmaceuticals. He sits on the board of Capella Bioscience, Impact Biomedicines and is currently chairman of Levicept Ltd., Apcintex and Crescendo Biologics, as well as being a board member of several other startups.

of Research in 1994 and, in 1997, Research Director and Chief Technology Officer. He led the development of CAT's platform technologies and their application in the discovery of a number of human antibodies, two of which are now on the market: Humira (Abbott Pharmaceuticals) and Benlysta (GlaxoSmithKline).

Kevin was part of the management team that floated CAT on the London Stock Exchange; it was subsequently acquired by AstraZeneca.

Madelaine’s prior experiences working in the biotech industry include program management at Prescience International, an award-winning firm dedicated to accelerating research to the patient, and CONNECT, an organization that catalyzes the creation of innovative technology and life sciences products in San Diego. Madelaine has a BA in Communications from the University of Washington.

32

Prior to joining Index, Kevin was with Cambridge Antibody Technology (CAT), where he was appointed Head

Kevin received a BSc in Molecular Biology from Edinburgh University and a PhD in Pathology from Cambridge University.

Peter Kendall is a fifth generation arable farmer from Eyeworth in East Bedfordshire who farms cereals in partnership with his brother Richard and mother. Peter took a degree in Agricultural Economics at Nottingham University before returning to what was a traditional mixed farm in 1984.

The farm today is a specialist arable unit that undertakes contract farming for a number of local farmers, cropping in total 2300 hectares.

President of the NFU for 8 years, his overriding passion has been to change the image of farming from a problematic old fashioned industry of the past, to one that is innovative, exciting and central to the big global challenges so clearly depicted by the UK Government’s Foresight Report on the Future of Food and Farming.

Dr. Klausner is founder and Director of Juno Therapeutics, founder and Director of GRAIL and Executive Chairman of Wisdo, a third generation internet company. He is the chairman of Mindstrong. He is the former Senior Vice President, Chief Medical Officer and Chief Opportunity Officer of Illumina Corporation. He is the former Executive Chairman of Audax Health. He currently Chairs the Grand Challenges in Cancer program of Cancer Research UK. Previously, he has served as managing partner of

In April 2014, Peter was appointed Chairman of AHDB, an organisation which exists to provide farmers and growers with the tools to grow UK farming. Following the EU Referendum in June 2016, UK agriculture will be facing a period of unprecedented change requiring the industry to face up to more international competition, lower financial support and greater need to focus on the customer. In this environment the work of AHDB will be more important than ever be that securing and developing new markets or ensuring we have the best technical tools to compete in international markets.

Sir Peter Kendall Chair, Agriculture and Horticulture Development Board

33

Peter received a Knighthood for his services to the agricultural industry in England and Wales in the Queen’s 2015 New Year’s Honours.

the Venture Capital firm, The Column Group, was the Executive Director for Global Health of the Bill and Melinda Gates Foundation. Dr Klausner was appointed by Presidents Clinton and Bush as the eleventh Director of the U.S. National Cancer Institute between 1995 and 2001. Dr. Klausner served as chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development as well as a past president of the American Society of Clinical Investigation. He has served in senior advisory

Dr Richard Klausner Founder and Director, Juno Therapeutics and Grail

Speakers

34

Dr Jeanne Lambrew, Senior Fellow, The Century Foundation

roles to the US, Norwegian, Qatari and Indian governments. He previously chaired the International Advisory Board for Samsung and chaired the Strategic Oversight Council of Sanofi.

He currently serves on numerous advisory boards. Dr. Klausner is well known for his work in cell and molecular biology, immunology and human genetics, and has been the author of more than 300 scientific articles and several books, in addition to receiving numerous awards, honorary degrees

and other honors. He has served as an Advisor to the Presidents of the Academies for counter-terrorism, and Liaison to the White House Office of Science & Technology Policy. He oversaw the writing of The National Science Education Standards, the first such standards for US Science Education. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.

Jeanne Lambrew, PhD, is a senior fellow at The Century Foundation.

Her writing, research, and teaching focus on policies to improve health care access, affordability, and quality.

Previously, she worked in the Obama Administration. In the first two years, she was the director of the Office of Health Reform at the U.S. Department of Health and Human Services (HHS).

In that role, she coordinated work toward passage and the implementation of the Affordable Care Act (ACA).

From 2011 to January 2017, she worked at the White House as the deputy assistant to the president for health policy.

In that capacity, she helped ensure execution of the president’s health policy agenda including implementation and defense of the ACA. Her portfolio also included policy regarding Medicare, Medicaid, the Children’s Health Insurance Program (CHIP), and public health. Prior to joining the Obama Administration, Lambrew was an associate professor at both the

Lyndon B. Johnson School of Public Affairs in Austin, Texas (2007–2008) and the George Washington University School of Public Health (2001–2007).

She also served as senior fellow for health policy at the Center for American Progress (2003–2007). Lambrew also served in the Clinton Administration in the HHS Office of the Assistant Secretary for Planning and Evaluation (1993–1995), the White House National Economic Council (1997– 1999), and the White House Office of Management and Budget (2000– 2001). In these roles, she helped coordinate health policy development, evaluated legislative proposals, and conducted and managed analyses and cost estimates with HHS and other relevant federal agencies. She received her master’s and doctoral degrees in health policy from University of North Carolina’s school of public health and her bachelor’s degree from Amherst College.

Jennifer is a trained health economist and biochemist. She completed her BSc in Biology/Biochemistry at the University of British Columbia, her MBA at the University of Calgary in Canada and her Postgraduate in Pharmacoeconomics in Melbourne, Australia. She began her career as a health economist in consulting in Sydney, Australia, before moving

onto a senior health economist role at Sanofi in Australia. She then moved to a regional health economist role based in Singapore with Sanofi, prior to moving to the UK and joining Janssen in 2012. She is currently the Director of Health Economics, Market Access, Reimbursement, Patient Advocacy and Government Affairs at Janssen UK.

Jennifer Lee Director of Health Economics, Market Access, Reimbursement, Patient Advocacy and Government Affairs, Janssen UK

Professor Chris Lowe is Emeritus Professor of Biotechnology in the Department of Chemical Engineering and Biotechnology, and Director of the Institute of Biotechnology at the University of Cambridge. He is also Director of the Cambridge Academy of Therapeutic Sciences. His principal research interests cover areas of healthcare biotechnology including biopharmaceuticals, diagnostics and sensors, ageing and medical microbiology. The work is characterised by not only being highly inter- and multi-disciplinary and encompassing aspects of biochemistry, microbiology, chemistry, electrochemistry, physics, electronics, medicine and chemical engineering, but also covering the entire range from pure science to strategic applied science, much of which has significant commercial applications. Professor Lowe has been the driving force for the establishment of 10 Spin-out companies,

and has been awarded several national and international prizes and distinctions, including the Pierce Award for Outstanding Contributions to the Field of Affinity Chromatography (1989), the David Curnow Prize in Clinical Chemistry (1991), Schlumberger Stichting Prize (1994), Queen’s Award for Technological Achievement (1996), Silver Jubilee Medal – Chromatographic Society (2002), Henry Dale Medal and Prize: The Royal Institution (London) (2003), Dade-Behring Award for Clinical Chemistry (2006), “Most Entrepreneurial Scientist of the UK” Award: UKSEC (2006), Queen’s Anniversary Prize for Higher and Further Education: The Royal Anniversary Trust (2007), Officer of the British Empire (OBE): New Year Honours (2010) and BBSRC Commercial Innovator of the Year (2011). He holds visiting Professorships at the Universities of Bath (UK), Lund (Sweden) and the Australian National University (ANU)(2013).

Professor Chris Lowe Director, Cambridge Academy of Therapeutic Sciences (CATS), University of Cambridge

35

Speakers Dr Simon Lucas Innovation Field Explorer, Merck KGaA

Simon Lucas is part of the Technology Foresight & Scouting team of Merck’s New Business Builder organization. In his role as an Innovation Field Explorer he is responsible for identifying, exploring, and developing unprecedented opportunities between and beyond the company’s existing offering. Simon joined Merck in 2018 from Evonik’s strategic innovation unit Creavis, where he was a project manager in the Sustainable Businesses unit, which supports the growth and sustainability strategy of Evonik by medium and long-term innovation

projects for existing and new growth fields. Prior to this, he held various positions in medicinal chemistry and drug discovery at Grünenthal, Aachen, and Boehringer Ingelheim’s oncology research center in Vienna. Simon studied chemistry in Munich and Saarbrücken and received a PhD in medicinal chemistry from Saarland University in 2008.

After postdoctoral stays at the University of Copenhagen and the Helmholtz Center for Infection Research, he began his career in the pharmaceutical industry in 2010.

Dr Kemal Malik Member of the Board of Management, Bayer AG

Kemal Malik was appointed to the Board of Management of Bayer AG effective February 1, 2014. He is responsible for Innovation and the Latin America region.

responsibility in medical affairs and clinical development at Bristol-Myers Squibb in the United Kingdom.

36

Kemal Malik was born in Slough, United Kingdom, on September 29, 1962. He studied medicine at Charing Cross and Westminster Medical School (University of London), graduating as a Bachelor of Medicine, Bachelor of Surgery (MBBS) in 1987. Malik subsequently spent several years in clinical medicine at the Northwick Park Clinical Research Centre and at Hammersmith Hospital, London. He then held various positions of increasing

Malik joined Bayer in 1995 as Head of Metabolism and Oncology Europe in the then Pharmaceuticals Business Group. He subsequently served as Head of Global Medical Development before being appointed Head of Global Development. Kemal Malik was a member of the Executive Committee of Bayer HealthCare AG from July 1, 2007 until his appointment to the Board of Management of Bayer AG. He was also Head of Global Development and Chief Medical Officer in the Pharmaceuticals Division.

Inventor, entrepreneur, and founder of life science companies to create new product categories in healthcare, nutrition, and agriculture.

Geoff is a founder of startups that have achieved over $3 billion in public and private market capitalization.

These include Indigo Agriculture, Seres Therapeutics (NASDAQ: MCRB), Axcella Health, Kaleido Biosciences, and Sienna Biopharmaceuticals, which respectively are pioneering plant microbiome products for crop improvement, microbiome therapeutics, amino acid-based drugs, novel chemistries to shape the human microbiome, and innovative medical dermatology products.

company's technology platform and led the development of the company's Indigo Cotton and Wheat commercial products. He was previously the Chief Technology Officer of Seres Therapeutics, where he led the discovery of SER-109 and build-out of the company’s discovery platform, and Vice President, Discovery of Axcella Health, where he led the discovery of two therapeutic products in human trials.

Geoff is Partner in Flagship Pioneering, Chief Executive Officer of Kaleido Biosciences, and Chief Technology Officer of Indigo. He recently served as President of Indigo, where he built the

His work has led to over 100 patent applications and patents, 20 peer-reviewed publications, as well as over 20 awards and honors, including the prestigious Lemelson-MIT Student Prize for invention and innovation. Geoff also has had his inventions recognized among the “world’s greatest scientific breakthroughs of today” by Dean Kamen on Planet Green and in the Innovations of the Year by MSNBC.

Adina Mangubat is the CEO and co-founder of Spiral Genetics, a leader in population genomics. Spiral Genetics makes software to analyze and compare large populations to enable the discovery of genetic variations important for diseases and conditions.

At Spiral Genetics, she leads complex sales to highly technical audiences, drives business development and product vision, and has built a diverse team of highly talented technical and scientific individuals to develop

the world’s most advanced bioinformatics technology. In addition, she is the primary catalyst for creating a transparent, high integrity, and mission-driven culture. Early in her career, Adina worked with two other high-technology companies wherein her role included team development, brand development, marketing, channel development and sales for complex technologies. A graduate of the University of Washington, Adina holds a B.S. in Psychology with a focus

Dr Geoffrey von Maltzahn Partner, Flagship Pioneering

37

Adina Mangubat, CEO and Co-founder, Spiral Genetics

Speakers on Entrepreneurship and was recognized by the Washington Biotechnology and Biomedical Association as one of the 2013 Women to Watch in Life Science. Additionally, she was featured in Forbes 2013 “30 under 30″ for Science and Healthcare. In 2017, Forbes named her as one of the All Star

Alumni for the 30 under 30 in Science and Healthcare. Adina’s passion for world-changing technology, coupled with her adept entrepreneurial focus and clear team development skills have enabled her to bring Spiral’s technology to the forefront of bioinformatics innovation.

Dr Oliver Martin Director Research & Development, Bayer Business Consulting

Oliver has joined Bayer AG in 2005, where he started at Bayer Business Services as Project Manager. Here, he undertook roles in IT Project Management for R&D and Management Consulting, before moving to Sao Paulo, Brazil to setup the first Bayer Business Consulting division for Latin America. Throughout this time, Oliver

occupied the position as Senior Project Manager. Following his role as Senior Project Manager, Oliver took over as the Director for Research and Development at Bayer Business Consulting, the role he currently occupies. Prior to joining Bayer AG, Oliver completed his PhD in Biochemistry at the University of Cologne.

Professor Baron Marc Van Montagu, Emeritus Professor, Ghent University

Em. Prof. Marc Van Montagu is a pioneer in plant molecular biology. He is well known (with J. Schell) as the discoverer of the Ti-plasmid and the inventor of Agrobacterium tumefaciens transformation technology, now used worldwide to produce genetically engineered plants. In addition to groundbreaking contributions to unravel the natural mechanism of gene

transfer in A. tumefaciens, the laboratory of Marc Van Montagu has applied gene transfer technology to study gene regulation and to discover the molecular basis of several plant physiological processes. He has given pioneering contributions on plant gene discovery and regulation, plant molecular mechanisms of response to abiotic stresses, and plant development. Dr. Marc Van

38

Montagu has been Founding Member and Member of the Board of directors of two Belgian biotech companies, spin-offs from his laboratory, Plant Genetic system (PGS) and CropDesign.

At PGS he has driven front-line innovations for biotech agriculture, such as plants resistant to insects or tolerant to more environmentally friendly herbicides. Dr. Marc Van Montagu has received numerous prestigious awards and honours, in particular the Japan Prize for Biotechnology and Agriculture Sciences in 1998, and the World Food Prize in 2013. He is member of 11 academies of sciences/agriculture

worldwide and recipient of 8 honorary doctorate degrees. Marc Van Montagu was the President of the European Federation of Biotechnologists from 2005-2013, and was appointed UNIDO Goodwill Ambassador for the development of agriculture in low-income countries in 2014. He has produced over 1100 scientific publications that have received more than 85.000 citations. Due to his accomplishments, he received in 1990 the title of Baron from the King of Belgians. Marc Van Montagu holds a PhD in Organic Chemistry/ Biochemistry and a BA in Chemistry from Ghent University.

39

Bernard Munos is founder and chief apostle of InnoThink, a consultancy dedicated to bringing evidence-based innovation models to the pharmaceutical industry. Previously an advisor for corporate strategy at Eli Lilly, he has long focused on disruptive innovation in drug development and on the radical redesign of R&D. Munos' research has been published in Nature and Science, and he has presented his findings to the National Academies, the Institute of Medicine, the President's Cancer Panel, the National Institutes of Health

Leadership Forum, the World Health Organization, the OECD, the Kauffman Foundation, the U.S. Patent and Trademark Office, the Council for American Medical Innovation and many others.

He received his M.B.A from Stanford University, and holds other graduate degrees in economics and animal science from the University of California, Davis and the Paris Institute of Technology for Life, Food and Environmental Sciences. In 2014, Bernard was among The 25 most influential people in biopharma.

Bernard Munos Senior Fellow, FasterCures (Milken Institute)

Speakers Dr Ameet Nathwani Executive Vice President, Chief Medical Officer / Global Head of Medical Function, Sanofi

A U.K. citizen, born in Uganda and educated in the U.K., Dr Nathwani qualified in medicine in 1987 in London, acquired his specialization in Cardiology at a number of University Hospitals in London, and has a diploma in Pharmaceutical Medicine and an executive Masters in Business Administration.

Dr. Nathwani has more than 20 years of experience in the pharmaceutical industry beginning in 1994 when he joined Glaxo Group Research. From the period of 1994 to 2004 he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, both

40

Dr Jane Osbourn Vice-President R&D, MedImmune

Jane Osbourn PhD is VP Research and Development and Site Leader for MedImmune in Cambridge, having joined MedImmune (formerly Cambridge Antibody Technology (CAT) and now the global biologics research and development arm of AstraZeneca) in 1993.

An expert in antibody engineering, she originated several key publications and

in Europe and US. He joined Novartis in 2004 as the Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise and over the period of 11 years has held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise. He was appointed as Global Head of Medical Affairs Novartis Pharma AG in June 2014 and became an extended member of the Pharma Executive Committee where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capability.

He was appointed to his present position in May 2016.

patents, and has also made a significant contribution to the discovery and development of marketed drugs (Humira and Benlysta) and more than 40 clinical candidates. Jane is Chair of the Board of Directors of the BioIndustry Association, a Director of Babraham Bioscience Technologies, a Director of Cambridge Enterprise and has presented at a number of parliamentary Select Committees.

Mene Pangalos is Executive Vice-President of AstraZeneca’s Innovative Medicines and Early Development Biotech Unit. A member of the company’s Senior Executive team, Mene has overall responsibility for the company’s pharmaceutical discovery research and early development activities.

Since joining AstraZeneca in 2010, Mene has been instrumental in rebuilding the company’s commitment to science and scientific excellence. He has led the transformation of R&D productivity; driven deeper collaborations with academic, biotech and peer organisations; pioneered programmes to promote Open Innovation and fostered a science driven culture that rewards great science and truth-seeking behaviours.

neuropharmacology and continues to mentor post docs and PhD students.

Mene has published more than 140 peer-reviewed articles in scientific journals and is an internationally renowned expert in neuroscience and drug discovery. He is a leading figure in UK science, serving on several Boards including the Medical Research Council, the National Centre for Universities and Business Council, the Ministers and Industry Strategy Group and the Cambridge Biomedical Campus Strategy Board.

Mene retains an active interest in neurodegenerative disease and

Mene is also overseeing the creation of AstraZeneca’s new £330 million research centre in Cambridge – a state of the art facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry.

Claus truly believes that better business is a significant key to creating a better world and has, throughout his career, focused on how to solve more societal challenges with a business model. For over 10 years, Claus has been the Head of Corporate Sustainability at Novozymes.

He works closely with its customers and partners to develop innovative solutions for solving environmental and social challenges, at speed and at scale, through core business activities.

Professionally engaged in sustainability

for more than 25 years, Claus was one of the pioneers in the development of Life Cycle Assessment (LCA) methodologies and sustainability concepts for business. As stakeholders have increasingly become engaged in Public Policy issues around the global sustainability agenda, Claus also took on the role of Head of Public Affairs for Novozymes in the EMEA Region. Claus is currently Novozymes Liaison Delegate to the World Business Council for Sustainable Development (WBCSD), Claus also

Dr Menelas N Pangalos FRSB FMedSci Executive Vice President, IMED Biotech Unit & Global Business Development, AstraZeneca

41

Dr Claus Stig Pedersen Head of Corporate Sustainability & EMEA Public Affairs, Novozymes

Speakers represents the company as a UN Global Compact LEAD member. He also serves in the Sustainability Council of Ingersoll Rand and sits on the Advisory Board of the Sustainable Brands organization.

Previously, Claus has served on sustainability boards and councils to Walmart, Procter & Gamble and The Sustainability Consortium. In 2016, the United Nations Global Compact recognized Claus for his work to align business with the sustainable development agenda, by naming him “Pioneer for Sustainable

Business Strategies”. Claus holds a M.Sc. in Chemical Engineering and a Ph.D. in Sustainability Management, and is an appointed Honorary Professor at the University of Aalborg and the Copenhagen Institute of Technology, where he contributes to the development of future leaders by teaching sustainability and business strategy.

Before joining Novozymes, Claus was leading the Global Sustainability and Quality activities of the Hartmann Packaging Group.

Dr. George Poste is the Del E. Webb Professor of Health Innovation and Chief Scientist, The Complex Adaptive Systems Initiative (CASI) (http://www. casi.asu.edu) at Arizona State University (ASU). This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision medicine and the remote monitoring of health status using miniaturized body sensors and mobile devices. He assumed this post in 2009. From 2003 to 2009 he directed and built the Biodesign Institute at ASU. He has published more than 350 research papers and edited 14 books on pharmaceutical technologies, cancer and infectious diseases. He has received honorary degrees in science, law and medicine for his research contributions.

He serves on the Board of Directors of Monsanto, Exelixis, Caris Life Sciences, and the Scientific Advisory Boards of the A. Alfred Taubman Medical Research Institute at the University of Michigan, Synthetic Genomics, Human Longevity Inc. and Haplogen GmbH. From 1992 to 1999, he was Chief Science and Technology Officer and President, R&D, of SmithKline Beecham (SB). During his tenure at SB, he was associated with the successful registration of multiple drug, vaccine and diagnostic products. He was named “R&D Scientist of the Year” by R&D Magazine (2004), he received the Einstein award from the Global Business Leadership Council (2006), the Scrip Lifetime Achievement award voted by the leadership of the global pharmaceutical industry (2009), and the Life Time Achievement award from the Arizona BioIndustry Association (2016). He is a

42

Dr George Poste Chief Scientist, Complex Adaptive Systems and Professor of Health Innovation, Arizona State University

Fellow of the U.K. Royal Society, the Royal College of Pathologists and the U.K. Academy of Medicine, a former Distinguished Fellow at the Hoover Institution, Stanford University, a member of the Council for Foreign Relations, a Governor of the Bulletin of Atomic Scientists, and a member of the U. S.

Institute of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.

43

Before joining Operation ASHA as a Director, Urvashi led a multi-million dollar health portfolio of the Michael & Susan Dell Foundation in India focused on improving the lives of the urban poor. During her tenure at the foundation, Urvashi catalysed school health programs that reached out to over 15 million children. She also formulated a school health implementation framework in collaboration with the Government and other stakeholders.

Urvashi has worked as a consultant for

the World Health Organisation and with the Partnership for Child Development, Imperial College London. Urvashi is also on the Governing Board of Partnership for TB Care & Control, India’s largest TB network. She is a World Economic Forum Global Shaper. Urvashi completed her Bachelors in Genetics from University of Birmingham followed by an MPhil in Bioscience Enterprise from University of Cambridge and an MSc in Public Health from the London School of Hygiene & Tropical Medicine.

Urvashi Prasad Public Policy Specialist, NITI Aayog, Government of India

Speakers Dr David Pyott Board Member of Philips, Alnylam and Biomarin; Philanthropist; Former Chairman of the Board and Chief Executive Officer, Allergan

Acknowledged as one of the top 100 performing CEOs in the world, Dr. David Pyott was the Chief Executive Officer of Allergan from 1998 until the sale of the company to Actavis in 2015.

By driving innovation through investments in R&D and impeccable performance, Dr. Pyott transformed Allergan from a small eye care company into a multi-billion dollar global specialty pharmaceutical and medical device company, overseeing $68 billion in market value growth. During his tenure Allergan launched blockbuster treatments that transformed medicine and skincare including expanding the approved uses of Botox to include treatment of migraine headaches, chronic tension headaches, cerebral palsy, severe over-active bladder and such cosmetic uses as brow furrows and crow's feet; as well as the development

of Restasis, a drug for the treatment of moderate to severe dry eye.

Molly Pyott Chairman, Easterseals Southern California

Molly Pyott currently serves as the Chairman of the Board at Easterseals Southern California. Molly joined California Healthcare (CHI) Institute in January 1995 as associate director of corporate communications. In April 1995, she was promoted to director of corporate communications. From April 2004 until April 2006, she served as vice president of corporate communications and marketing, and has served as vice president of operations since then. From 2010 until 2015 Molly Pyott served as the CHI's Vice President of Business Development. Prior to joining CHI, she was publications

manager and medical and science editor for Scripps Health, an integrated healthcare delivery system that includes Scripps Clinic and Research Foundation, Scripps Memorial Hospitals and an independent physician's network in La Jolla, Calif. Previously, Pyott managed public relations for Boulder Community Hospital and the Mapleton Center for Rehabilitation in Boulder, Colo. Her professional affiliations include membership in the American Society of Association Executives. She holds a bachelor's degree in journalism from the University of Colorado, Boulder.

44

For Dr. Pyott, improving patient outcomes is paramount. He wants what is best for his employees, his shareholders and the company as a whole; that’s why when he believes in something, he fights for it. His dedication and fortitude has been instrumental in building his track record for transforming business and society. At Allergan, he promoted the importance of research and development for innovation and growth. He felt so strongly about this that he refused to give in to lucrative acquisition attempts because he did not believe in the acquiring company’s business model of cutting and slashing R&D budgets that created alternate innovative uses for Botox to improve patient lives.

David was appointed Chief Strategy Officer in May 2008 and is responsible for corporate development and strategic planning. In addition to his current role, he was appointed Chairman of the Board of ViiV Healthcare Ltd. in April 2011 and non-executive director of the Aspen Pharmacare Ltd. Board in February 2015. He is a member of the Corporate Executive Team.

Previously, he was Senior Vice President, Northern Europe with responsibility for managing GSK's pharmaceutical businesses in that region and, prior to that, was Senior Vice President for Central and Eastern Europe. David joined GSK in 1994 and was Finance Director of the European business from 1999 to 2002.

David Redfern Chief Strategy Officer, GlaxoSmithKline

David has a Bachelor of Science degree from Bristol University in the UK and is a Chartered Accountant.

45

Dr. Rhee serves as Chief Health Officer of IBM, where he has global responsibilities for Watson Health and assuring a Culture of Health at IBM. Prior to joining IBM, Dr. Rhee was Chief Public Health Officer at the Health Resources and Services Administration (HRSA), which is the primary federal agency for improving access to health care services for people who are uninsured, isolated, or medically vulnerable. Dr. Rhee also served as Director of the Office of Innovation and Program Coordination at the National Institutes of Health (NIH), which is the primary federal agency for research. Prior to his federal government service, he worked in community health settings as the Chief Medical Officer of Baltimore Medical System Inc., the largest network of Federally Qualified Health Centers in Maryland. In addition, Dr.

Rhee served five years as a National Health Service Corps Scholar and Medical Director at Upper Cardozo Health Center, the largest community health center in Washington, DC. Dr. Rhee was a Chief Resident and performed his medical residency training in both internal medicine and pediatrics at Cedars-Sinai Medical Center in Los Angeles. He obtained his medical degree from the University of Southern California. Dr. Rhee also holds a master's degree in public policy from the John F. Kennedy School of Government, Harvard University with a concentration in Health Care Policy.

He acquired his Bachelor in Science degree from Yale University in Molecular Biophysics and Biochemistry.

Dr Kyu Rhee Vice President and Chief Health Officer, IBM Corporation and IBM Watson Health

Speakers Melinda Richter Global Head, Johnson & Johnson Innovation, JLABS

46

Sandra Sassow CEO and co-founder, SEaB Energy

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson’s sectors: consumer, medical device and pharmaceuticals.

Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning

the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set out to create a better model, which now forms the basis for JLABS’ operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also initiated, raised capital and secured large corporate deals for several companies in both the life science and technology space.

She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and a MBA from INSEAD in France. Melinda is an active board member and Treasurer of the California Life Sciences Association (CLSA).

Sandra Sassow is the CEO and co-founder of SEaB Energy. SEaB Energy was founded with the purpose of working towards a future in which cities or remote communities can capitalise on their waste to create renewable sources of energy and curb the negative impacts of waste collection processes.

SEaB Energy’s shipping container devices can be placed behind community locations such as grocery stores and hospitals, where they use bacteria to anaerobically digest organic waste

created at that location and produce usable fertiliser, electricity and water as a result. Sandra’s effort in being a role model for women in business innovation and actively influencing the green tech sector through both technological and business development has been globally recognised and appraised with several awards and nominations, the most recent being an invitation to participate, with 15 other entrepreneurs, in the first Unreasonable Goals accelerator program - a public-private

partnership between the U.S. Department of State and Unreasonable Group – having SEaB Energy representing Global Goal number 13, Climate Change (from the United Nations Sustainable Development Goals). This September, Sandra collected the Spotlight on Women in STEM at the Women in Business Awards and was shortlisted ‘Entrepreneur of the Year’ at the Investor Allstars Awards. Through Sandra, SEaB Energy was featured in CNBC, BBC and WIRED and was selected from over 500 applicants by the

NASA-backed sustainability initiative, ‘LAUNCH: Beyond Waste,’ as a provider of a global game-changing technology to address climate change. Additionally, Sandra is Business Director of the Solent Local Enterprise Partnership, member of WeConnect and the Chartered Institute of Waste Managers and mentor of Southampton Science Park Catalyst Program. Sandra combines her professional activities with an active family life as mother of four and enjoys horseback riding in her spare time.

47

Dr. Raymond F. Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University and co-Director of the HIV Cure Scientific Working Group for the NIH-sponsored Emory University Center for AIDS Research (CFAR). He has authored over 550 peer-reviewed papers and 7 books and holds over 100 issued US patents, which have resulted in 15 New Drug Applications (NDA). A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV, HBV and HCV drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine), LdT (telbivudine), and sofosbuvir (Sovaldi), which are all

approved by the US FDA. More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented.

Dr. Schinazi served on the Presidential Commission on AIDS. He is the recipient of numerous awards including the 2015 William S. Middleton Award from the Department of Veterans Affairs, which is the highest honor for outstanding achievement in biomedical research. He is also the recipient of the 2016 Institute of Human Virology’s Lifetime Achievement Award for Public Service and 2016 Scrip Lifetime Achievement Award. Dr. Schinazi is internationally recognized as one of the most influential persons in the life science sector.

Prof Raymond F. Schinazi, Frances Winship Walters Professor of Pediatrics and Chemistry, Director of Laboratory of Biochemical Pharmacology, Emory University

Speakers Matthew Scholz CTO, Immusoft

Matthew Scholz is Immusoft’s founder and Chief Technology Officer.

His curiosity about how the body attacks invading pathogens and stores the information sparked his idea for Immusoft. He realized that he could modify technology developed by Nobel Laureate David Baltimore to program resting B cells to secrete therapeutic proteins. The modified system is the core of Immusoft’s technology platform, Immune System Programming™. Immusoft, which under Matthew’s leadership is transitioning

from a research biotech to a clinical company, has raised capital from the U.S. National Institutes of Health, Peter Thiel’s Breakout Labs, Founders Fund Science, and prominent private investors, including Tim Draper and the former head of preclinical development at Seattle Genetics. Matthew has a degree in computer science. He is a mentor for the Thiel Fellowship, a program that awards grants to some of the brightest scientific minds in the world under age 20.

Dr Kelvin Stott Director of Portfolio Management, Novartis

Kelvin is currently Director of Portfolio Management at Novartis in Basel, Switzerland, where he is responsible for evaluating project and portfolio investment decisions to support the company’s global drug development pipeline. He is a globally recognized and respected thought leader in biopharma innovation and R&D productivity, with over 20 years of experience in various roles across big pharma (Novartis, Merck Serono), biotech start-ups (Senexis), management consulting (McKinsey, PwC,

Quantelium) and venture capital (Inventages). A firm believer in the importance and need for unconventional critical strategic thinking to challenge and disrupt the status quo, he lives by the entrepreneurial spirit and motto to “aim high, think big and different, start small, fail cheap and learn fast”. Kelvin holds a PhD in protein engineering from Trinity College at the University of Cambridge, and was also a Research Fellow at Peterhouse.

48

Brindan Suresh is a partner in McKinsey’s London Office, specialising in healthcare. Brindan studied and obtained a BA (Govt), LLB (HonsI) and an MD from the University of Sydney - his key areas of expertise now lie within Healthcare Systems and Services, Pharmaceutical ‘Go to Market Models’, Medical Affairs and Strategy and organization design.

Brindan has recently been working on several projects including: working with NHS leaders in London on

large scale integrated care provision involving 2m+ patients, supporting the launch of new products for a number of pharmacos and their commercial business units, re-designing the strategy, structure and operations for a number of global and regional R&D/ Medical Affairs organisations across a range of pharmacos and working with a major pharmaco to establish the role of digital channels in boosting overall productivity/process efficiency and customer engagement.

Dr Brindan Suresh Partner, McKinsey & Company

49

Shrikumar Suryanarayan is the Chairman and co-founder of Sea6 Energy Pvt. Ltd. (www.sea6energy. com). The company was founded in 2010 and is focused on the development of technology for offshore biomass production and conversion to a variety of bioproducts, including agricultural biostimulants renewable fuels and chemicals.

Shrikumar was formerly the President of Research and Development and Chief Scientific Advisor at Biocon Limited, the largest life-science company in India (www.biocon. com) for over 25 years. He also served as the Chief Executive officer for the Translational Health Sciences Institute

(www.thsti.res.in) at the National Capital Region Biosciences Cluster, Government of India from 2009-2010

Shrikumar has B.Tech in Chemical Engineering from the Indian Institute of Technology Madras and a Masters in Biotechnology from the Indian Institute of Technology, Delhi, He was conferred the “Distinguished Alumnus Award ” of the Indian Institute of Technology, Madras in 2009 and was chosen as “Entrepreneur of the year” by Biospectrum magazine in 2012. Shrikumar has been elected to become the President of the Association of Biotechnology Led Enterprises of India ( ABLE ) starting April 2018.

Dr Shrikumar Suryanarayan Managing Director, Sea6 Energy PVT LTD

Speakers Dr Jan van de Winkel President and CEO, Genmab A/S

Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel has over 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab.

He is the author of over 300 scientific publications and has been responsible

for over 70 patents and pending patent applications. Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University. He is chairman of the board of directors of Hookipa Biotech AG, member of the board of directors of LEO Pharma and Celdara Medical, the scientific advisory board of Thuja Capital Healthcare Fund and the advisory board of Capricorn Health-tech Fund. He holds M.S. and Ph.D. degrees from the University of Nijmegen.

Sir Gregory Winter Master, Trinity College Cambridge

Professor Sir Gregory Winter became Master of Trinity College on 2nd October 2012. He is the former Deputy Director of the MRC Laboratory of Molecular Biology at Cambridge, and is best known for his research and inventions relating to humanised and human therapeutic antibodies. He pioneered techniques that have led to antibody therapies for cancer, and diseases such as rheumatoid arthritis and multiple sclerosis.

Centre for Protein Engineering, and during this time he also founded three Cambridge biotech companies based on his inventions: Cambridge Antibody Technology (acquired by AstraZeneca), Domantis (acquired by GlaxoSmithKline) and Bicycle Therapeutics. Sir Gregory is a non-executive Director of Bicycle Therapeutics, and a Trustee of the Newton Trust, the Cambridge Commonwealth Trust, the Cambridge Overseas Trust and the Kennedy Trust for Rheumatology Research.

50

Sir Gregory is a graduate of Trinity College. His research career was based almost entirely in Cambridge at the Medical Research Council’s Laboratory of Molecular Biology and the

He was appointed CBE in 1997, and was then knighted in 2004. In 2013 he received the MRC Millennium Medal.

Dr. Margaret Zeigler is the Executive Director, Global Harvest Initiative (GHI). She is a thought leader in the international agriculture and food security arena with expertise in international poverty alleviation, agricultural development, organizational leadership and program management. She has worked in non-partisan and multi-stakeholder engagement and collaboration with a variety of food security organizations and institutions, including United Nations agencies, NGO’s, U.S. government and the OECD, regional development institutions, foundations and the private sector.

GHI is a collaborative private-sector voice to advance sustainable agriculture solutions for meeting the world’s growing demand for food, feed, fiber and fuel. As the global population increases to nearly 9.7 billion in 2050, along with rising incomes and changing consumer preferences, GHI proposes five key

policy goals that will enhance global agricultural productivity while conserving natural resources.

Dr. Zeigler speaks in domestic and international venues about how these policies along with public-private partnerships are advancing global food security and agricultural productivity. Dr. Zeigler co-authors the annual Global Agricultural Productivity Report® (GAP Report®) published by the Global Harvest Initiative, and is a regular media contributor. She holds a Ph.D. and M.A. in Geography and International Development Studies and between 1997 and 2001 was an adjunct faculty member at the Elliott School of International Affairs at George Washington University, Washington, DC. She serves on the Scientific Advisory Council of the United States Foundation for Food and Agriculture Research (FFAR) and is on the board of directors for the Association for International Agriculture and Rural Development (AIARD).

Dr Margaret Zeigler Executive Director, Global Harvest Initiative

51

Leaders of Tomorrow Solomon Abiola Joint PhD Candidate Translational Biomedical Sciences and Computer Science, University of Rochester School of Medicine

Solomon is a joint-PhD at the University of Rochester School of Medicine, focusing on the application of AI/big data approaches to health. His thesis Node, used mHealth to predict the spread of Ebola in Nigeria, receiving international accolades from the NSF,

World Health Summit, Falling Walls, and Super Bowl. He has degrees in Mechanical and Aerospace (Princeton), and Biomedical Engineering (CMU).

While working with Apple on the mPower Parkinson’s app, Merck KGaA, and MC10 Inc.

Carolina Aguila Díaz Biotechnology Engineer, Andrés Bello University

Scientist, Speaker, Writer and Entrepreneur. Biotechnology Engineer from Andrés Bello University, Chile. Driven by her motivation and passion in biomedicine, Carolina was a co-author in publications in the area of stems cells and cancer research. Winner of numerous programs and recognized

by influential organizations like 100 Women Leaders, Global Solution Program at Singularity University located at NASA Research Park, Young Leaders Chile, etc. Also volunteering for different organizations. She has no limits and excuses to help the people around the world.

Amadeus Driando Ahnan Founder, Indonesian Tempe Movement and PhD Student, University of Massachusetts Amherst

Amadeus Driando Ahnan is a food scientist, artist, social entrepreneur, and musician. Amadeus is pursuing his PhD in Food Science at University of Massachusetts Amherst, focusing on food bioactive compound and colon cancer; a founder-coordinator

of Indonesian Tempe Movement, which aims to give people access to affordable, sustainable, and nutritious protein source by promoting tempeh; the Vice Chair of Research Chefs Association and former Vice President of IFT Student Association.

Alexander Aivazidis Graduate Scientist, AstraZeneca

I am physicist by training, who got fascinated by the complexities of biology and the prospect to improve human health. After an MSci in Physics at Imperial College London and an MPhil in Computational & Systems

Biology at Cambridge University, I am now a Graduate Scientist on the Early Development Graduate Program at AstraZeneca, where we get to work on different stages and techniques of the drug development process.

52

Ahmed is currently working as strategic information consultant in HIV and Hepatitis with the Division of Communicable Diseases at the Eastern Mediterranean Regional office of WHO. He received his training in Public Health, Epidemiology from High Institute of Public Health in Alexandria and Harvard T.H. Chan

School of Public Health in 2015. He is highly interested in the integration of healthcare innovation in public health practices. In this regard, he conducted the first survey mapping healthcare innovation in Cairo in 2016 setting a platform for the scope of health innovation.

Ahmed Sabry Alaama Strategic Information Consultant/ Division of Communicable Diseases, WHO

Muhammad Ali is a Biochemistry Major at University of Karachi and Health Security Futures Fellow at Health Security Partners. He is an explorer by nature and loves to take things apart and put them together.

Technology and Biosciences are his interests and nothing excites him more than a creative fusion of them.

He led Pakistan’s first iGEM Team, which developed a Biosensor for pollutants and won Bronze Medal in the International Synthetic Biology Competition at Boston, USA. He has also represented Pakistan as a youth ambassador in USA on a student exchange scholarship.

Muhammad Ali Undergraduate Student, Department of Biochemistry, University of Karachi

M. Can Anadol is a consultant at Bayer Business Consulting who aims to further unify science and business by asking the right questions that drive innovation and progress in R&D. Having acquired his MSc degree in Microbiology and Immunology from ETH

Zurich, Can also serves as the youngest member on the board of directors of the Swiss Association for Competitive Intelligence, Market Research and Strategic Insights.

M. Can Anadol Business Consultant, Bayer Business Consulting

I graduated in Biomedical Engineering at Carlos III University, Spain, with an exchange year at UC San Diego. During that time I interned at The Scripps Research Institute (CA) and the MD Anderson Cancer Centre (TX). Shortly

afterwards I completed my MSc in Biomedical Engineering at Imperial College. I currently work at GSK, focusing on new drug delivery devices, creating physical and math models and ensuring their safety during use.

David Bazaga Applied Mechanical Engineer Associate, GSK

53

Leaders of Tomorrow Jake Becraft PhD Student, MIT

Jake Becraft is a fifth year PhD candidate in the Biological Engineering Department at MIT under the advising of Professor Ron Weiss. Jake is involved in the MIT Biotech Group’s Investment Due Diligence team, exploring his interest in start-ups, venture capital, and venture creation.

He is also active in the MIT Science Policy Initiative and serves as a Science and Technology advisor to a freshman legislator in the Massachusetts State House and is a consultant for a number of local Tech and Biotech VCs.

José Manuel Besares López MPH Public Health (International Health) Student, The University of Nottingham

Manuel (born 19 March 1992, in Cardenas, Tabasco) is a Genomic Biotechnologist from Mexico. He focuses on Health Promotion and Prevention of the Infectious Diseases like HIV/AIDS and Zika. Recognised for his leadership in the Biological and

Health Sciences, he won the prestigious Chevening Scholarship of The United Kingdom in 2016. As Alumnus of the US State Department, and the FCO of the UK, he is part of the “100 Young Leaders of the Biotechnology in Latin America”.

Akash Bhattacharjee Masters student in Biomedical Engineering, Imperial College London

Akash Bhattacharjee is a Masters student studying Biomedical Engineering, specialising in Biomaterials and Tissue Engineering, at Imperial College London. He was awarded the Grand Prize and 5 major Prizes at iGEM (International Genetically Engineered Machine) 2016, having represented Imperial at the world’s

largest Synthetic Biology competition.

He has developed experience across multiple disciplines of Biochemical and Bioengineering research through internships at the Institute of Cancer Research, the Photosynthesis and the Biomolecular Systems groups at Imperial.

Madhura Bhave PhD Student, Nanyang Technological University, Singapore

I am a PhD student in the School of Chemical and Biomedical Engineering at Nanyang Technological University, Singapore. My research focuses on Bacterial Cancer Therapy, a niche area involving the application of bacterial derivatives for the inhibition of

cancer. As I approach the end of my doctoral studies, I seek new opportunities to continue my work in healthcare technology development, which will bring new, innovative solutions to address the most pressing needs of patients.

54

Roshni is an undergraduate student at National Institute of Technology, Rourkela in India where she is majoring in Computer Science & Engineering. She is a Caltech undergraduate research fellow and has worked with the Biotechnology and Planetary Protection Team at NASA's Jet

Propulsion Laboratory. Her current interests lie at the intersection of Bioinformatics and Artificial Intelligence. Outside of academics, Roshni organizes and participates in community service projects, serving as the President of Leo Club of Rourkela.

Roshni Biswas Undergraduate student, National Institute of Technology, India

Having completed his BSc in Plant Sciences, he is currently in his final year of MSc Plant Biotechnology at Wageningen University. Noteworthy achievements are amongst others Chairmanship of the Wageningen University association of Plant Sciences

and an Honours programme in China.

In addition, he is an iGEM team member for his university and writing a proposal for a PhD. “My ambition is to steer biotechnology in a positive way; facilitating responsible solutions to global problems”.

Damian Boer MSc Student in Plant Biotechnology, Wageningen University

55

Bio-entrepreneur with a strong interest in neurological disorders. Cofounder of Expesicor, which develops diagnostics and therapeutics for neurological

disorders, and its sister company, Fyr Diagnostics, which focuses on miRNA research.

David Booth Co-founder and COO, Expesicor

Roger Castells-Graells, PhD student at the John Innes Centre (JIC), is studying the structure of viruses to develop bio-nanotechnological tools like nanomachines. His undergraduate degree was in Biotechnology at the Autonomous University of Barcelona.

He was member of a finalist team in

the Biotechnology YES 2017 competition. Roger is also passionate about 3D printing and science communication. In 2014, he started WhatIf (www.whatifnet.science), an innovative educational project aiming to bring science to students.”

Roger Castells-Graells PhD student, John Innes Centre

Leaders of Tomorrow Ricardo Camilo Chávez Martínez Founder, Scintia

Ricardo holds a MSc. Systems and Synthetic Biology from the University of Edinburgh, and is a proud iGEM veteran. He is currently a Lecturer ITESM, Engineering department, and

is the founder of Scintia, a start-up focusing on developing affordable biotech tools and services for the Latin-American landscape.

Kellen Chen Graduate Student, University of Virginia

I’m studying Biomedical Engineering at the University of Virginia, specifically on the effect of mechanical loading on scar healing. I was born in Boston, raised in California, and went to UC Berkeley for my undergraduate degree in bioengineering.

After graduation (expected Fall 2018), I want to design and test new biotechnologies and help integrate them for patient usage. In my free time, I like to play volleyball, eat delicious food, and watch the NFL/NBA.

Catriona Corbishley Research Scientist, Global High Throughput Screening, AstraZeneca

In July 2017, I gained an Integrated Biochemistry Master’s from the University of Liverpool. As part of this, I spent my final year within AstraZeneca’s Safety Screening Centre, where I assessed nephrotoxicity in human iPSC-derived renal cells using a novel biochemical endpoint. I now

work within AstraZeneca’s Global High Throughput Screening group as a Research Scientist, conducting biochemical and cell-based screens to support target selection and, hit and lead identification during early drug development.

Tinne Amalie Damgaard Nissen Graduate Student at Schwartz Group, Novo Nordisk Foundation Center, University of Copenhagen

Tinne is studying a master in molecular biomedicine at the University of Copenhagen specializing in molecular pharmacology, and metabolism. Tinne is a board member in the non-profit organization Synapse and a board member in the Danish Biotechnological Society. Her work in

these organizations includes leading an ambitious mentorship program connecting students and industry professionals and co-organizing an international biotech conference.

Tinne is very interested in how we can accelerate innovation by connecting academia and industry.

56

Ann is a New Technology Associate in the Asia-Pacific New Technologies Team at Cook Medical Australia. She is responsible for scouting and assessing new technologies within the Asia-Pacific region and matching these technologies to the right business areas of the company globally.

Ann graduated from the University of Queensland with a Bachelor of Biotechnology (Molecular Sciences & Innovation Management) with First class honors and is a certified Project Management Professional by the Project Management Institute.

Ann Damien New Technology Associate, Cook Medical Australia

Bianca is a researcher from São Paulo, Brazil. She holds a bachelor degree in Nursing (FICSAE) and studied Biomedical Science (University of Greenwich) where she was able to develop a project that combined cell immunology with patient care. She trained as a nurse at MD Anderson Cancer Centre (USA) and set herself apart as

an outstanding scientist by earning 1st place as a Young Researcher at VII International Nursing Symposium.

Despite her young age, she specialized in applying her expertise and enthusiasm by bringing solutions to consumer goods and pharmaceutical companies.

Bianca de Leon Clinical Research Analyst, Kimberly-Clark Corporation

Stephen Ducray is a Marie Curie Early Stage Research Fellow pursuing a PhD through the University of Cambridge. As part of the European Union’s Horizon 2020 Marie Skłodowska-Curie Innovative Training Network ‘ALKATRAS’, he is researching the oncogenic

fusion protein NPM-ALK in driving Anaplastic Large Cell Lymphoma.

Stephen is interested in networking both in academia and industry, and is enthusiastic to learn more about the biotechnology, healthcare and pharmaceutical industries.

Stephen P. Ducray Marie Curie Early Stage Research Fellow, University of Cambridge

I’ve finished my MSc. of Interdisciplinary Sciences at ETH in Zurich in 2017. During my studies research visits have brought me to Japan, America as well as England,

where I decided to stay for my PhD. I’m now trying to teach cells how to synthesize completely programmable unnatural polymers.

Daniel Dunkelmann PhD Candidate, MRC Laboratory of Molecular Biology, University of Cambridge

57

Leaders of Tomorrow Varshit Dusad Masters Student in Systems & Synthetic Biology, Imperial College London

I am passionate about Synthetic Biology and its real-world applications. I am highly motivated towards entrepreneurship and plan to utilize my research skills to establish my own start-up in synthetic biology.

Currently, I am looking forward to

networking with like-minded people - students, founders and industrial veterans. I believe that advances in technology, effective communication and right policies will shape the future of synthetic biology.

Mohamed Elzek Graduate Research Assistant at the Cambridge Systems Biology Centre, University of Cambridge

After completing his medical degree at the University of Alexandria, Egypt, Mohamed co-founded Egybiotech, the first biotech start-up in Egypt. Throughout his four years as chief scientific officer, he developed the company's portfolio in areas of public health surveillance.

His current research interests primarily combine advanced molecular biology approaches and machine learning techniques to translational systems biomedicine, especially in DNA damage response with potential applications in ageing research.

SofĂ­a Esteban Serna Undergraduate Student, University College London

I am from Las Palmas de Gran Canaria (Spain). After finishing high school, I received an athletic scholarship to study in the US for a year. In 2016, I started my Biochemistry degree at University College London, which I

will be representing at the Hult Prize Regional Finals this year. Hoping to pursue a career in scientific research, I am interested in maximising its positive impact on society geographically and chronologically.

Diogo Feleciano PhD Candidate, Leibniz FMP Berlin

I am currently doing my PhD at Leibniz FMP Berlin, where I am studying the underlying mechanisms involved in aging and neurodegenerative conditions. Prior to this, I obtained my Biochemistry from the University of Coimbra and moved on

to Imperial College London to work on the pathways involved in ocular diseases. I believe that biotech will have a great impact on people’s lives in the near future and I want to give my contribution.

58

Rasmus is an ambitious and hardworking undergraduate student with a strong passion for biotechnology and entrepreneurship. Since his second year at the Technical University of Denmark, he has been involved in an

international research project, and has presented his work around the world. As a co-founder of the company VenomAid Diagnostics, he is on a mission to reduce the global burden of snakebite envenoming.

Rasmus Friis Undergraduate Student, Technical University of Denmark

Active DIY biologist for 5 years (head of LA Biohackers iGem 2014).

Researched at LiuLab at UCI for 4 years developing directed evolution system and new mitochondrial transformation techniques. Interested in

inexpensive combinatorial assembly, genome synthesis, and democratizing those arts for everyone. Currently works for the BioBricks Foundation in Endylab at Stanford.

Keoni Gandall Head of Free Genes Project, BioBricks Foundation

59

Lilian (1991) was born and raised in Santa Cruz de la Sierra, Bolivia. She was an outstanding student at the German School of Santa Cruz,where she also participated at the International Baccalaureate Program. Her strong interest in genetics motivated

her to study biotechnology in Germany earning a BSc degree in Biotechnology.

She currently studies the Master Program in Medical Biotechnology at the TU Berlin. Lilian was named AllBiotech leader and ambassador to Bolivia and Europe in 2017.

Lilian Gonzรกlez Auza MSc Student in Medical Biotechnology, Technical University of Berlin

Sam Gray is a final year Medical Student in Trinity College Dublin.

During an intercalated MSc in Neuroscience he became excited by Biotech Entrepreneurship, Economics and Policy. A founder of the Trinity Healthcare Entrepreneurship Forum, he has interned at 3D4Medical Software,

Novartis Pharmaceuticals, and the World Health Organisation in Geneva.

Sam Gray Medical Student, Trinity College Dublin

At home in Dublin, he enjoys the occasional good singsong.

Leaders of Tomorrow Dominic Hall MRes Student at the Cambridge Stem Cell Institute, University of Cambridge

My name is Dominic Hall and I am a graduate from the Mathematics Tripos at the University of Cambridge where I specialised in theoretical physics. I and am now enrolled on a PhD programme at the Cambridge Stem Cell Institute and hope to use my

mathematical background to approach socially and environmentally relevant problems that biotechnology has potential to tackle. My key interests are sustainability and mathematical modelling and computation.

Phoebe Heseltine PhD Student, University College London

Phoebe Heseltine is a PhD student in the Department of Mechanical Engineering at University College London.

She received her BSc in Nanotechnology from the University of Leeds.

Following an MSc in Biomaterials and Tissue Engineering, Phoebe was

awarded an EPSRC studentship and joined the Biomaterials Processing Laboratory of Prof. Mohan Edirisinghe in 2017. Her current research is focused on manufacturing polymeric devices for use in vascular engineering.

Christopher Huang Master’s student, University of Oxford

Chris is currently a student at the University of Oxford reading for a master’s in Molecular and Cellular Biochemistry and will join the global management consultancy firm McKinsey & Company shortly after

graduating this October. He is fascinated by the impact that advances in biotechnology can have on the world and is keen to learn about the roles he can play in shaping the future of the industry.

Raja Jain ​Undergraduate Student, Indian Institute of Technology Roorkee

Raja is a third-year undergraduate student at Department of Biotechnology, Indian Institute of Technology (IIT) Roorkee, India. He recently won the "Go Green in the City" challenge, an annual flagship competition of Schneider Electric dedicated to

sustainability and clean energy, for his low-cost air cooler. He's now working to improve the design and soon going to launch it in the market. In his free time, he enjoys reading books and traveling to new places.

60

Mani works at the Community Biotechnology Initiative, MIT-Media Lab. He is an AIV Master’s candidate at CRI-Paris. His research interests include microfluidics, synthetic biology and bio-inspired engineering.

Taking advantage of his background in mechanical engineering

in bachelors from BITS-Pilani and synthetic biology in masters from CRI-Paris, he works on interface of engineering and biology, low-cost bio devices and frugal science. Before joining the Media Lab, he did research work at MIT-Meche, Ecole Polytechnique and INSERM.

Mani Sai Suryateja Jammalamadaka Researcher at Community Biotechnology Initiative, MIT Media Lab

Saylee moved to the UK from Pune, India to pursue a BEng in Bioengineering at The University of Sheffield in 2014. She spent a year working in Research and Development for Reckitt Benckiser, focusing on the marketing and technical maintenance of medical

devices. Her passion for bridging the inequality in healthcare between developing and developed countries is shown through her advancing research on a low-cost diagnostic for dengue fever in Vietnam.

Saylee Jangam Undergraduate Student, University of Sheffield

61

Hello, I am Cecilia, an industrial engineering masters graduate from Chalmers University of Technology.

I come from an intellectual property and technology management background. I grew up in an international house, a dual nationality; Swedish/ Indian, and by the age of 20 I had lived in 8 countries and 11 cities ranging

from Asia, Middle East, Europe and West Africa, this naturally shaped my interests for sustainability and social innovation. I am very interested in packaging and managing early staged knowledge and research. I completed my work and master thesis at Palo Alto Research Centre in Silicon Valley.

Cecilia Johansson Business Developer, Smecke Invest AB

As a graduate student I have studied both the peripheral and central nervous systems, and currently research the neurodegenerative disease amyotrophic lateral sclerosis (ALS) in the Maragakis Lab. My thesis aims to uncover the mechanisms behind ALS disease progression and

explore therapeutic targets. Outside the lab, my focus is to understand the biotech realm and the complexities of drug development, both in classroom settings and through leading the Entrepreneurship arm of the Hopkins Biotech Network.

Jessica Joseph PhD Student in the Cellular & Molecular Medicine Program, Johns Hopkins University School of Medicine

Leaders of Tomorrow Marketta Kachemov Neuroscience PhD Student, University of California

I am a neuroscience PhD student at the University of California, Irvine where I study molecular mechanisms of neurodegeneration in Huntington’s disease. In May 2016, I received my bachelors of science in genetics, cell and developmental biology from

Barrett, the Honors College at Arizona State University. I am passionate about all things biotechnology, from industry to science policy, and upon graduation I intend to pursue an impactful career in the biotech community.

Sweekrity Kanodia MSc Student, Imperial College London

I am Sweekrity Kanodia from Imperial College, London. I am currently pursuing MSc in Biomedical EngineeringMedical Physics and Imaging. I did my BSc in Biotechnology from Bangalore, India. I come from Kapilvastu, Nepal. I have a dream

to make Nepal research intensive. Due to poor funding and no opportunities for Biotechnology graduates, Biotechnology is not really in demand there. I want to change this scenario and Gap Summit is the first step to my dream.

Michael Kasimatis PhD Student, Imperial College London

Michael is a PhD student at Imperial College London, investigating wearable sensors and flexible electronics. He is driven by the opportunity to make difference for the better.

He co-founded BlakBear, a start-up aiming to democratise sensing by

enabling smartphones to measure citywide air-pollution, and other chemicals. Originally from the south of Athens, he currently lives by the canals of west London, always looking for driven people to collaborate with.

Ali Javaid Khan Co-Founder & CEO, Serena

I am a fresh graduate from the University of Hong Kong with a major in Biomedical Engineering, and work experiences in Tissue Engineering, Hardware Development and Robotics.

Teaching is my side passion and I have multiple experiences in teaching

Sciences, Coding and English. I’m currently learning Data Science and Machine Learning, hoping to bring Big Data and AI related solutions to the Healthcare Industry, as well as setting up my own start-up.

62

Klara is a first year PhD student at the Centre of Misfolding Disease in Cambridge in the group of Prof. Michele Vendruscolo. In her PhD project she uses an in silico design method to develop antibodies targeting tau, a protein associated with Alzheimer’s disease. Coming from a background in

Biophysics (B.Sc. and M.Sc. in Physics, Ludwig Maximilian University, Munich) she applied different single molecule microscopy techniques to study biomedical problems. During her studies in Munich, she continuously worked for start-ups such as Kinexon or Flixbus.

Klara Kulenkampff PhD Student at the Centre of Misfolding Diseases, University of Cambridge

Originally from south Florida, I am currently studying the role of transcription factor cooperation in breast cancer progression at Georgetown University in Washington, DC. Before this, I worked at Medline Industries in product development and strategy,

helping identify market needs and position products for government approval. I am passionate about using my scientific background to develop new technologies to improve patient care. I’m excited to be a part of GapSummit!

Max H. Kushner PhD Candidate, Georgetown University

63

Prior to my PhD, I received a master degree from Max F. Perutz Laboratories, Vienna. During this time I tackled the anti-tumour use of CRISPR/Cas9 and became immensely attracted to developing new therapeutic strategies. Now, I am deciphering the role of

tumour microenvironment in chemoresistance of cancer cells. In parallel, I lead a student association “Integration for Graduates in Biology”; dedicated to promote innovative ideas, networking and career development of young researchers.

Sanya-Eduarda Kuzet PhD student, Institute for Research on Cancer and Ageing, France

During 2011-2014 I obtained my Bachelor of Science in ‘Molecular Biology’ at the University of Bielefeld, Germany.

Afterwards I studied ‘Regenerative Biology and Medicine’ at the Center for Regenerative Therapies Dresden, Germany and received my Master’s

degree in 2016. Since 2017 I am a PhD student in the Dresden International Graduate School for Biomedicine and Bioengineering at the faculty for Medical Systems Biology in Dresden, Germany.

Felix Lansing PhD Student, Dresden International Graduate School for Biomedicine and Bioengineering

Leaders of Tomorrow Wojciech Lason Undergraduate Student, University College London

Wojciech is an aspiring researcher with a particular interest in immunology and cancer biology. Growing up in Poland, he got hooked on science through a high school project. It led him to becoming a national finalist of EU Contest for Young Scientists.

He enjoys communicating scientific breakthroughs to a wider audience and organises National Pathology Week at UCL. Outside academia, Wojciech is a keen language learner and a contemporary dancer.

Rafaela Prado Scientist, Bayer Crop Science

Bachelor in Biotechnology at Federal University of Alfenas with a sandwich period at the University of Kentucky, USA. Founding member and Chief Executive Officer of the Junior Biotechnology Company , BIOTEC INOVA, at UNIFAL-MG. Master’s of Science in Plant Science at Federal

University of Viçosa where developed research in genomics on the Coffee Biotechnology Laboratory located at the Biotechnology Institute Applied to Agriculture. Currently works at Bayer – Crop Science Division as Scientist on Trait Research.

Sissi Lin Research Fellow, Molecular Engineering Laboratory, Agency for Science, Technology and Research (A*STAR)

Sissi is a committed scientist, an enthusiastic science communicator and an aspiring entrepreneur.

She is a research fellow at A*STAR in Singapore and a project leader of interdisciplinary projects on DNA-based technologies. With good

communication skills and a strong entrepreneurial spirit, she has been advocating for science through public talks and scientific stories, and is driven to bring technology to market for benefits of people. She is also an active supporter for working mums.

Michael MacDonald PhD Student, ARC Centre for Biopharmaceutical Innovation, University of Queensland

I am fascinated by the complexity and order of living things. Coupled with a drive to help people I decided to pursue a career in pharma R&D, specifically focusing on biopharmaceuticals. To these ends I graduated with a master’s degree in chemical

and biological engineering at the University of Queensland, Australia.

64

I have since worked with Patheon Biologics, and am now undertaking a PhD in cell line development and perfusion processes.

Lea received her B.Sc. in Life Sciences and M.Sc. in Bioengineering from the Ecole Polytechnique Federale de Lausanne in Switzerland in 2013. After graduation, she spent 5 months in The Gambia at the Medical Research Council UK Unit working on a malaria

epidemiological study. Since 2014 Lea is pursuing a Ph.D. in Molecular Engineering at the University of Chicago.

Her thesis research focuses on the roles of lymphatic’s in cancer development and immune regulation.

Lea Maillat Ph.D. Candidate, University of Chicago

Rakitha Malewana is a Sri Lankan medical inventor, entrepreneur, and youth activist. His basic research work is primarily based on medical and molecular biology with the special interest in Cancer and HIV. He started his research career at the age of 15

and developed a ground-breaking nano-vaccine for HIV. Currently, his life science company “Hamzter” is creating breakthroughs in life science and advocating global health issues that will make a difference for a better tomorrow.

Rakitha Malewana Founder and CEO, Hamzter

65

Ragav is a medical student at UCL with a background in medical physics and bioengineering. He has international experience in medical technology and has worked with the WHO, Roche and Accenture on projects related to cardiovascular devices and health technology for low-resource settings.

He led the UCL Entrepreneurs Society as President and invested in 7 start-ups across 2015/16. Through co-founding Kickstart London, the first student-run pre-accelerator across London, he’s accelerated 16 high-impact start-ups since 2015.

Ragav Manimaran Medical Student, UCL | Co-founder, Kickstart London

Antoni is a researcher and MSc student at the National Institute of Molecular Biology and Biotechnology of the University of the Philippines Diliman. As part of the national drug discovery program of the Philippines, he has validated bioactive hits from primary screens using high-content

imaging-based orthogonal assays.

Currently, he is investigating the molecular basis of X-linked dystonia-parkinsonism, a neurodegenerative disease that is common among individuals whose ancestry can be traced back to Panay Island, Philippines.

Antoni Andreu Martija Science Research Specialist, University of the Philippines

Leaders of Tomorrow Alexandra Mattei PhD Candidate, Harvard University

Alexandra Mattei is a PhD candidate at Harvard University and currently a visiting scholar at the Max Planck Institute for Molecular Genetics in Berlin. Alexandra is broadly interested in studying the transmission of information between cells, and from generation to generation. Her

thesis work investigates the epigenetic regulation of mammalian development, with a specific focus on DNA methylation. She is passionate about teaching, outreach, and making molecular biology more approachable to the general public.

Nick Matthews PhD Student, University of Manchester

Nick Matthews is a PhD student at the University of Manchester. Originally from Bristol, UK, his undergraduate education was at the University of Cambridge where he studied Natural Sciences followed by an MSci in Systems Biology. Nick’s doctoral

research focuses on how constructive and anticipatory approaches can be used to assess the sustainability implications of synthetic biology and biotechnology innovations at low technology readiness levels.

Alex Mayorov Undergraduate Student, University of Cambridge

Born in Moscow, Russia, I moved to the U.K. five years ago. I’m currently in my 3rd year studying chemistry at the University of Cambridge. In addition to chemistry, my interests include biotechnology and computer science.

I participated in the iGEM competition as part of Cambridge-JIC team 2016 and am a member of the Youth Biotech international community. In my free time, I enjoy practising yoga and scuba-diving.

W. Alex Meltzer Director of Business Development, Early Charm Ventures, LLC.

I am Alex Meltzer and I currently live in Baltimore, MD. Recently, I defended my Ph.D. thesis and now work for a biotech venture creation firm. My day-to-day tasks include market discovery, new product development, raising capital and growth strategy

for multiple biotech start-ups. I also currently serve as COO/cofounder of a health services company, AgamiLife, Inc. Outside of biotech, I also serve as an executive board member of a non-profit.

66

I am currently working as the Climate Change Advocacy Coordinator at CARE International in Vanuatu.

Involve in the climate change project and programs with the civil societies. Currently the community youth leader, leading youths in the community development projects to improve community wellbeing.

I have a Master Degree in Environmental Science from the University of New Caledonia. First Ever Queen Year Leader received from Queen Elizabeth II an award for the community services in Vanuatu, in June 2015.

Willy Missack Climate Change Advocacy Coordinator, CARE International, Vanuatu

Nelli is a final year undergraduate at the University of Cambridge, where she is studying Pharmacology and Human Genetics. After graduating, she is planning to pursue a research career in nanomedicine, developing drug delivery systems. She is enthusiastic

about attracting more attention to scientific discoveries from the public and is on the organising committee for Cambridge University Biological Society and the undergraduate science and technology conference.

Nelli Morgulchik Undergraduate Student, Natural Sciences, University of Cambridge 67

I am currently a student of the Master’s Program in Business Creation and Entrepreneurship in Biomedicine at the University of Gothenburg.

The program is centred on business management and entrepreneurship

with a specialization in intellectual property within the life-sciences field.

I graduated with First Class Honours degree in Physiotherapy and also Sports Sciences, both from Alfonso X El Sabio University (Madrid).

Francisco Mosteiro MSc Student, University of Gothenburg

A scientist by training and an entrepreneur at heart, Som aspires to bring about a positive change within the global bio-economy. He holds a Master's degree from the Indian Institute of Technology, Bombay and currently serves as Chairperson

of BioBiz -a biomedical conference, where he strives to offer an interactive platform for students and industry professionals to explore career opportunities and business insights. In his free time, Som enjoys long drives and motor sports.

Somsubhro Mukherjee PhD Student, National University of Singapore

Leaders of Tomorrow Arthur Neuberger PhD candidate in Pharmacology & Biochemistry, University of Cambridge

I am a final year PhD student at the Department of Biochemistry (Luisi group). I use a combination of cryo-electron microscopy and functional assays to structurally and functionally characterise membrane proteins involved in antimicrobial resistance. Prior to starting my

PhD, I read for an MPhil in Management Science and Operations at the Cambridge Judge Business School.

Since then, in an on-going international collaboration, I have co-authored research papers exploring success parameters in biopharmaceutical drug development.

Fanice Mangoja Nyatigo Undergraduate Student, University of California, Berkeley

Fanice is an undergraduate researcher at the Fletcher lab in Berkeley’s bioengineering department. Her work, under the tutelage of a PhD student, combines concepts in machine learning and optical microscopy to develop new technology for medical diagnostics. She is also passionate about the improvement of healthcare

delivery in low-income settings, which led her to start MamaTips, a subscription service through which pregnant women in rural Kenya get health tips specific to their gestation stage. Outside school and her projects, Fanice enjoys salsa dancing, singing in the choir and travelling.

Celeste Peh National Business Development Manager, Chiasma

I am an aspiring innovator and entrepreneur in the Biotechnology industry, having recently graduated with Master of Bioscience Enterprise and BSc (Biomedical Science) specialising in Neuroscience at The University of Auckland. I am the National Business Development Manager for

Chiasma, an organisation creating links between STEM, academia, and businesses. Being involved in the start-up ecosystem in New Zealand, my passion lies in innovation, collaboration, and commercialisation of science, particularly in the medical and healthcare space.

Ignacio Perez-Pozuelo PhD Candidate in Medical Sciences, University of Cambridge

Ignacio Perez-Pozuelo was born in Madrid, Spain and is a PhD student in Medical Sciences at Cambridge. Ignacio obtained a Master’s degree in Bioengineering from the University of California at Berkeley and UCSF as well as a Master’s in Neuroscience from the

University of Oxford. He completed his undergraduate studies at Brown University in Bioengineering, and a Marie-Curie Early Career Fellowship in Cognitive Neuroscience at the University of Cambridge.

68

I am currently a PhD student at the University of Cambridge, looking at developing new therapeutics aimed at treating pathologies that stem from dysfunctional mitochondria. I am a trained pharmacist and have worked in the pharmaceutical industry and

am passionate about the development of new medicines to treat diseases.

I am extremely looking forward to tackling the challenges of tomorrow together with the rest of the members of Gap Summit!

Hiran Prag PhD Candidate, University of Cambridge

My name is Victoria and I am working as a Graduate Scientist at AstraZeneca. Alongside work, I am also chairing one of our company’s Early Talent networks – AZ Youth Gothenburg. Prior to working in industry, I obtained a Master’s degree in Medical Science; Biomedicine from Lund University in Sweden.

I have always been passionate about taking on challenges within biotechnology and medicine. My particular interest lies in facilitating great discoveries through innovation and collaboration.

Victoria Ptasinski Graduate Scientist, AstraZeneca

Winnie is the founder and CEO of Haalthy, a venture backed company that collect complete and real-time medical data with a vision to create an "intelligent pill" to make cancer

treatment truly personalised. Listed as one of the Forbes 30Under30 in China, she held a MS Degree from MIT and worked as an engineer consultant in New York after graduation.

Winnie Qiu Founder and CEO, Haalthy

Master of biotechnology (MSc.) focused on researching the development of bioeconomy in Slovenia and Europe. Founder and CEO of Start-up Company PharSol, whose goal is to

help biotech and pharmaceutical industry with products and services.

Passionate about start-ups in the life sciences and improving the transition from academia to industry.

Miha Rajh CEO and Founder, PharSol

69

Leaders of Tomorrow Caoimhe Reid Bioproduction Scientist, Horizon Discovery

Caoimhe Reid is a Trinity College Dublin Immunology graduate. She previously worked as a Bio-Production Scientist in Horizon Discovery, Cambridge. She now works as a Process Scientist on the Upstream Drug Substance Technical Services

team in Pfizer, Dublin. Her role involves facilitating the technical transfer of mammalian cell culture to Pfizer Grange Castle. Caoimhe has a passion for molecular biology and organic chemistry and aspires to work in such fields in the future.

Pamela Inés Rellstab Sánchez MASc Student and Research Assistant, University of British Columbia

I have been working as a Research Assistant at UBCO for the past 7 months before starting my Master in Mechanical Engineering this January. I have a Bachelor’s Degree in Biotechnology Engineering and a bit of experience in different research facilities worldwide.

My research has led me to collaborate

in several multidisciplinary and multicultural projects in fields that include molecular diagnostics, biomaterials, tissue engineering, chaotic flows, entrepreneurship, cultural inclusion, social impact and most recently microfluidics.

Manon Ricard MSc Management student, Imperial College Business School

Manon is a French national, aged 22, who has lived abroad in several European countries. During her years in Sweden, she participated in the iGEM competition and became passionate about preventive and personalised medicine. After graduating from

Karolinska Institutet with a BSc in Biomedicine, she is now studying an MSc in Management at Imperial College to prepare herself for the development of business ventures in the area of new life science technologies.

Claire Richards Operations Global Graduate, AstraZeneca

Claire is interested in how businesses can positively contribute to society.

She is a Global Graduate within Supply Chain and Strategy at AstraZeneca, and has operations experience within Nissan, George Utz and the NHS. Claire completed her BA in Philosophy and Politics at Durham University, and

MSc in CEMS/International Management at ESADE Business School and Rotterdam School of Management.

Claire is passionate about volunteering; she led charitable expeditions to Cambodia and India. She enjoys acting, the outdoors, and playing the piano.

70

I am currently completing my Masters in Medical Biotechnology at Wageningen University and Research in the Netherlands. Previously, I finished my Bachelors of Science and Arts at the University of Sydney majoring in molecular biology and ancient history.

I am interested in synthetic biology, finding more economical ways to produce therapeutics and CRISPR. I am also passionate about malnutrition, the global food crisis and want to find ways to empower local communities through the STEM.

Lizzie Richardson Masters student of Medical Biotechnology, Wageningen University and Research

Born in 1990, I come from Montenegro. When I was 19, I went to Italy to study Molecular Biotechnology in Torino. During my studies, I worked in the cancer biology lab of Prof.

Carola Ponzeto and bioinformatics lab

of Prof. Paolo Provero. After Master’s in Italy, I went to Switzerland to do PhD at EPFL in Lausanne. Now, I’m in the laboratory of Prof. Jacques Fellay studying human genomics of immune system and infectious diseases.

Petar Scepanovic PhD Student, EPFL

71

Hello, I’m Vaibhavi! I am a freshman at the Massachusetts Institute of Technology (MIT) studying Brain and Cognitive Sciences and Biological Engineering. I am currently interested in exploring the biotechnology industry and the cross between modern innovation and global

interconnectedness. I am working on policy solutions for biotechnology development, especially as it relates to entrepreneurial initiatives and public health. In the past, I’ve worked on projects for artificial intelligence applications to medicine and neurosurgical research.

Vaibhavi Shah Undergraduate Student, Massachusetts Institute of Technology

Rohan Shah is currently a sophomore undergraduate at Princeton University concentrating in Molecular Biology and Entrepreneurship. Most recently, Rohan interned in immuno-oncology at Jounce Therapeutics where he was exposed to the preclinical, clinical, and venture capital dimensions of biotechnology. He credits his initial interest

in biotechnology to a prior research internship at Memorial Sloan-Kettering in the laboratory of Dr. Charles L. Sawyers where he studied mechanisms of cancer drug resistance.

Rohan is specifically interested in addressing challenges in research and development productivity.

Rohan Shah Undergraduate Student, Princeton University

Leaders of Tomorrow Nilesh Sharma Undergraduate Student, Karolinska Institute

I am studying Bachelor of Science in Neuroscience at the University of Calgary; however, I am currently on an exchange at Karolinska Institute. I have worked on two biotech projects as a UCalgary iGEM (an international synthetic biology competition) member, learning the

value of an integrative approach in applied sciences. I am passionate towards reforming education to advance innovation, and I hope to incorporate biotech and neuroscience to develop novel technologies for treating neurological disorders.

Sihinta Shembil Operations Executive, LEAP

Sihinta Shembil is an enthusiastic B.S. Biotechnologist pursuing Masters in English Literature. She grew up in five different countries where she experienced the magic of biodiversity and the importance of connecting with incredible people. Hence, Sihinta’s future aspirations revolve around Science

Communication.

Outside studies, she dedicates her time to LEAP, a non-profit organization inspired by Precious Plastic, freelance writing for Bangladesh’s leading English newspaper and is a proud-chartered member and newsletter editor for Toastmasters.

Svenja Siemer PhD Student, Mainz University Medical Centre

Svenja Siemer is a PhD student at Mainz University Medical Centre, concentrating on the biological impact of nanomaterials. She holds a BSc in Biochemistry, a MSc in Biotechnology, and gathered internship experience in consulting. A

passionate believer that biotechnology can change our life for the better, she is a member of the biotechnology student initiative and hopes to be able to facilitate the transition from great ideas into great products in the future.

Jashan Preet Singh ​Undergraduate Researcher, Indian Institute of Technology Roorkee

Undergraduate Researcher in the field of Diagnostics and Nanotechnology at IIT Roorkee, India. Having 5 years of experience in Robotics and 3 years in Product Development, I wish to implement my skills in developing low-cost Point-of-care healthcare

diagnostic devices. Past Internship at the University of Manchester working with Graphene and DNA aptamers. I believe that detecting a disease and analyzing the affected will solve half the problem of finding a cure.

72

Max grew up in Beijing, Shanghai and Chicago, and studied machine learning and diplomacy at Brown University.

Previously worked at NASA Ames on genetic engineering, as a Teaching Fellow at Singularity University, co-founded Brown’s first start-up accelerator, and worked in Silicon Valley as Ayasdi’s youngest data scientist.

Co-published thedatasciencehandbook. com, modelled Citibanks 2015 Stress Test, started the One Salon—an experiential community that spread from Stanford to 12 cities. I’m working in a HK-based company branching out into other projects, including biotech + AI, blockchain/cryptocurrencies, sustainability, and renewables.

Max Song Investor, Nan Fung Group

Sreenath is an aspiring Global Leader, Innovator and Bio-Entrepreneur, with a strong social conscience. His goal is to transit from academia to industry via a science-based start-up in the healthcare industry and strive to make a global impact. As the Students’ Head for Biofest 2017, the

annual biotechnology fest of IIT Madras, Sreenath has a rich background in leadership, public speaking, team management and team work and a strong passion for biotechnology.

He is also passionate about football, music, travel and food.

Sreenath Srikrishnan Undergraduate Student, Indian Institute of Technology Madras

Ricardo Suarez-Heredia is currently PhD Candidate at the Advanced Centre for Biochemical Engineering from University College London (UK). Given his interest in business and finance for Biotech sector, Ricardo also receives education and training at London

Business School and London School of Economics. He aims to contribute to promote an academia-industry nexus platform for biomanufacturing at international, multidisciplinary and intergenerational levels.

Ricardo Suarez Heredia PhD candidate in Biochemical Engineering, University College London

I am Anjana Sundarrajan, first year masters student in biotechnology at University of Pennsylvania. I am working as a research assistant under Dr.Mecky Pohlschröder developing glycoproteome for Haloferax volcanii, an archaea, which usually lives in extreme salt conditions. I did my

undergraduate studies in pharmaceutical sciences in Manipal University, India. When I am not running gels in the lab, you can find me reading medical thriller novels and writing about science and Indian politics.

Anjana Sundarrajan Master’s student in biotechnology, University of Pennsylvania

73

Leaders of Tomorrow Zsófia Sveiczer Undergraduate Student, New York University Abu Dhabi

Currently completing my undergraduate studies at New York University Abu Dhabi, majoring in Cognitive Neuroscience. During my education, I had the privilege to study all around the globe (UAE, China, US, Ghana) and conduct research in the field of

genomics, neurobiology and cognitive neuropsychology. As a Global Career Peer I also try and do facilitate personal growth and professional development among students, especially those who intend to major in a STEM field.

Ruben Tadmor Master's Student in Systems Biology, University of Cambridge

I am currently studying for a Master’s in Systems Biology at the University of Cambridge and have undertaken research projects in the fields of molecular genetics, structural biology, proteomics and bioinformatics. My interests include the potential uses of multi-omics data

for precision medicine, and tackling the problem of antibiotic resistance.

I am also interested in translational research, having worked on a Cambridge Technology iTeams project to commercialise new research into peptide stapling.

Diana Tamayo Undergraduate Student, Tecnológico de Monterrey Campus Guadalajara, Mexico

Diana Tamayo was born on June 25th, 1997, in Guadalajara, Mexico. Her interests lie in Natural Sciences and Scenic Arts. In December 2016, she was invited to attend the COP13-MOP8 with other students as part of the PRRI

NGO. Diana participated in 2017’s IGEM competition where she helped serving as a Student Leader. She is part of Youth Biotech and serves as a Fellow Science Communicator at ISGP’s “The Forum”.

Sasha Tolstoy Graduate student at Molecular Neuropharmacology and Genetics Lab, Dept. of Neuroscience, University of Copenhagen

Sasha soon holds a M.Sc. degree in Molecular Biomedicine from University of Copenhagen with a specialization in immunology and experimental neuroscience. Sasha is a managing board member of the non-profit organization Synapse, where she leads an international seminar to England and

helps organize interactive workshops to bridge the gap between academia and the life science industry. Sasha is greatly inspired by biotech innovations and personalised medicine emerging in the industry and plans to add business administration to her scientific qualifications.

74

I was born in Colombia but raised in Panama, and I completed a degree in Optical Engineering at the University of Rochester in Rochester, New York.

I’m currently a member of the Laser Analytics Group in the Department of Chemical Engineering at the University

of Cambridge. My PhD research is in adaptive optics for three-dimensional imaging of neurodegenerative processes in vitro. Outside the lab, I enjoy surfing, rowing, listening to The Killers, and doing yoga.

Pedro Vallejo Ramirez PhD Candidate in Biotechnology, University of Cambridge

Julianna, half Filipino and half Hungarian, grew up in the Philippines and moved to Munich in 2015 to pursue her studies in biology. She is currently 20 years old and is on the final year of her bachelor. She is interested in molecular biomedical science and this

research field’s implications for the treatment of disease. Mixed with Julianna’s curiosity for technology, she is particularly interested in the ‘digitalised healthcare and personalised medicine’ gap.

Julianna Varga Undergraduate Student, Ludwig Maximilian University Munich

Thomas did his PhD thesis with Prof.

Dr. Sebastian Jessberger at the Brain Research Center in Zurich. His work aims to understand how posttranslational modifications of proteins are affected by distinct metabolic states in

the context of stem cell quiescence and proliferation. Thomas was supported by a fellowship of the Boehringer Ingelheim fonds (BIF). After his PhD with distinction end of 2017 Thomas continues his work as postdoc.

Dr Thomas Wegleiter Postdoctoral Fellow, University of Zurich

Elise is a PhD Student in the Harvard-MIT Health, Sciences and Technology Program focusing on the ability of tissue-engineered cellular scaffolds to modulate the immune system in models of lung and tracheal transplantation. She received a B.S.

in Biomedical Engineering from Yale University where she studied paracrine signaling between cells in 3D constructs and the development of tissue engineered lungs from decellularized scaffolds. Elise is from Seattle, WA and enjoys running.

Elise Wilcox PhD Student in Medical Engineering and Medical Physics, MIT

75

Leaders of Tomorrow Henry Zubaida Analyst, Merck Ventures

76

ŠChris Williamson

Henry is an analyst in the New Businesses fund of Merck Ventures. Henry has an academic background in chemistry and recently completed a Masters in Bioscience Enterprise at the University of Cambridge; during this time he was awarded the Cambridge University Entrepreneurs - Young

Entrepreneur of the Year prize. During his master’s he undertook an internship at Merck KGaA Innovation Center working in a think tank focused on Blockchain applications in healthcare.

Prior to this, he worked as a management consultant.

Voices of Tomorrow Competition

78

ŠChris Williamson

The Voices of Tomorrow competition is designed to provide a platform for inspiring and supporting Leaders of Tomorrow in biotechnology worldwide to develop breakthrough solutions to challenges in the global bioeconomy.

Teams were formed from 100 selected Leaders of Tomorrow to develop ideas for innovative projects to practically solve a problem identified. Guided by mentors, each team submitted

an initial project proposal, and the 8 best teams were chosen as finalists to pitch their ideas to a panel of expert judges during the GapSummit 2018.

Overall, teams were working on their business proposals from January until April 2018.

Following the pitches, the top three teams will be commended by the judges and awarded prizes, which will include additional mentorship

from McKinsey & Company to help them further develop and implement their project proposals. An additional ÂŁ3,000 and ÂŁ2,000 will be awarded to the first-placed and runner-up teams respectively, to further support the development of their idea into a reality. Seed prizes for the first placed and second placed team are associated with the successful completion of given milestones during the early development of the venture.

Ventures grown

by Leaders

of Tomorrow through the

ng Repurposi

Dev elo

jugates (ADC s

Ab

y

iotechno l og

s

n co

oject m h pr an ec t a o

me ge nt a nd c o

ing platfor nd m fu

)

t en

ra s for re dis ea ug r d

se

antibody-dr ug ng i p

Bi

GapSummits

r fo

cancer trea tm

ns

u

n tio lta (Additional key ventures by our LoTs are also currently in development)

Voices of Tomorrow Finalist Selection Panel Prof Alan Barrell Entrepeneur in Residence Judge Business School, University of Cambridge

Alan Barrell DBA FRSA has spent almost 30 years in senior executive positions in technology based industries and has become one of Cambridge's most articulate promoters of entrepreneurship.

He has been the Entrepreneur in Residence at the Centre for Entrepreneurial Learning within the Judge Business School at the University of Cambridge.

He was a founder shareholder in Library House Ltd, and is now a Visiting Professor of Enterprise at the University of Bedfordshire School of Graduate Business Studies. He is also Distinguished Guest Professor at Xiamen University, Visiting Professor at Shanghai College of Science and Technology and at the Fujian International School of Economics and Business, Fuzhou and Guanzi University, all in China.

80

He has taught at Tsinghua University Beijing, Fudan University in Shanghai Miranda Weston-Smith Business Development Consultant, BioBeat Founder

and Minjiang University, Fuzhou City.

He acts as Consultant to the China (Shanghai) Public Practicing Base for Entrepreneurs. His interest in China, its history, people and culture has become a major feature of his life and work. Other appointments include Senior Enterprise Fellow, University of Essex, International Fellow, Anglia Ruskin University Cambridge, and International Research Fellow, Laurea University of Applied Sciences in Helsinki.

Alan was instrumental in launching the Cambridge Gateway Fund, a â‚Ź70 million fund, to support early stage technology businesses in the region and became its Managing Partner, and he has been involved with a number of charities including the Papworth Trust, the Royal Society of Arts, the Centre for Tomorrow's Company and The Prince's Trust.

Miranda helps early stage biomedical businesses attract investment and develop their business strategy. She is a Coach for the SME Instrument of the European Commission, long standing Mentor for Cambridge Judge Business School’s Entrepreneurship Centre, contributes to the University of Cambridge Masters in Bioscience Enterprise course, and founded and runs BioBeat, an innovation platform for bioentrepreneurs.

Her experience includes working at Cambridge Enterprise, where she licensed and spun out life science technologies, and the seed capital firm, Cambridge Research and Innovation.

She has worked with many entrepreneurs on fundraising, business planning and technology transfer.

www.mws-consulting.co.uk @BioBeatUK

Miranda studied Natural Sciences at the University of Cambridge and has a Diploma from the Chartered Institute of Management Accountants. She is a Fellow of the Linnean Society, and has edited eight science books.

Voices of Tomorrow Judges As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.

By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson’s sectors: consumer, medical device and pharmaceuticals.

Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient.

Melinda founded Prescience after she had a medical emergency that left her

Dr. Matthias Evers is a Senior Partner in McKinsey’s Hamburg office and co-leader of the EMEA Pharmaceuticals and Medical Products (PMP) R&D and Medical Practice. Since joining the firm in 2002, Matthias engaged with pharmaceuticals clients in EU but also in the US and in Asia transforming R&D organisations to overcome innovation and productivity issues through deeprooted transformatory approaches; especially with focus on critical junctures and capabilities in early clinical development and in the late-stage clinical, medical, and commercialization space. In addition, he has engaged in

questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set out to create a better model, which now forms the basis for JLABS’ operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also initiated, raised capital and secured large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and a MBA from INSEAD in France. Melinda is an active board member and Treasurer of the California Life Sciences Association (CLSA).

Chair: Melinda Richter Global Head, Johnson & Johnson Innovation, JLABS

translating learnings between innovator and generics R&D (e.g. on biosimilars) as well as supporting a cross-industry dialog on drug innovation in multiple settings in Europe and the U.S.

Dr Matthias Evers Senior Partner, McKinsey & Company

Matthias holds a Ph.D. in Chemistry/ Biochemistry from the University of Bochum with a particular focus on Neuroscience. Before his career with McKinsey, he worked as a Research Associate and Postdoctorate at a Center for Molecular Neurobiology in Hamburg.

He authored several articles in the field of bioinformatics and molecular biology.

81

Voices of Tomorrow Judges Dr Christoph Hüls Head of Technology Foresight & Scouting, Chief Innovation Officer, Merck KGaA

Christoph Hüls is responsible for the corporate innovation strategy and the technology foresight at Merck KGaA, Darmstadt, Germany. He is experienced in different businesses at Merck in Healthcare as well as Performance Materials (specialty chemicals).

Including operational excellence in R&D, licensing, bio-partnering as well as the Corporate Venture Fund of Merck. Before joining Merck in 2008, he was CEO of Protagen AG, a German biotech company focussing on high-value services in protein analysis especially under GMP, tool and software development for R&D in proteomics and the development of diagnostics based on a technology platform around protein biochips.

He managed there several rounds of financing for the development of

diagnostics as well as the build-up of a profitable service business in protein analysis. From 1999 to 2001 Christoph was responsible for project and portfolio management at Azupharma GmbH and CoKG, the German subsidiary of the Generics business of the Novartis group. He started his professional career in 1994 at Hoechst AG. After two years in the pharma division of Hoechst (today Sanofi) in Rheumatology/Immunology early phase drug development, he was working in increasing responsibility on projects in cell adhesion, protein evolution and RNA-splicing in the Central Research department.

Christoph received his PhD in Biology from the Johannes-Gutenberg-University in Mainz at the Institute of Immunology.

Dr Sohaib Mir Investment Associate, Cambridge Innovation Capital

Sohaib is an Investment Associate focusing on a range of healthcare investments.

Birmingham where he also completed a PhD in CNS regeneration. In addition Sohaib holds an MPhil in Bioscience Enterprise from the University of Cambridge.

82

Prior to joining CIC in 2014 he worked at Perella Weinberg Partners (London) within the Healthcare M&A team.

Before this, Sohaib practised Medicine at Addenbrooke’s Hospital. He qualified in Medicine from the University of

Sohaib has prime responsibility for Fluidic Analytics and is also on the board of Exvastat.

Dr. Margaret Zeigler is the Executive Director, Global Harvest Initiative (GHI). She is a thought leader in the international agriculture and food security arena with expertise in international poverty alleviation, agricultural development, organizational leadership and program management.

She has worked in non-partisan and multi-stakeholder engagement and collaboration with a variety of food security organizations and institutions, including United Nations agencies, NGO’s, U.S. government and the OECD, regional development institutions, foundations and the private sector.

GHI is a collaborative private-sector voice to advance sustainable agriculture solutions for meeting the world’s growing demand for food, feed, fiber and fuel. As the global population increases to nearly 9.7 billion in 2050, along with rising incomes and changing consumer preferences, GHI proposes five key policy goals

that will enhance global agricultural productivity while conserving natural resources.

Dr. Zeigler speaks in domestic and international venues about how these policies along with public-private partnerships are advancing global food security and agricultural productivity. Dr. Zeigler co-authors the annual Global Agricultural Productivity Report® (GAP Report®) published by the Global Harvest Initiative, and is a regular media contributor. She holds a Ph.D. and M.A. in Geography and International Development Studies and between 1997 and 2001 was an adjunct faculty member at the Elliott School of International Affairs at George Washington University, Washington, DC. She serves on the Scientific Advisory Council of the United States Foundation for Food and Agriculture Research (FFAR) and is on the board of directors for the Association for International Agriculture and Rural Development (AIARD).

Dr Margaret Zeigler Executive Director, Global Harvest Initiative

83

Voices of Tomorrow Mentors Chibeza Agley

Chibeza Chintu Agley holds a MSc degree, with distinction, in Human and Applied Physiology from King’s College London. He finished at the top of his class and received the Colt Foundation Prize for 'Best Research Project'.

Following his MSc, Chibeza was awarded funding from King’s College London to pursue a PhD which focused on cell fate decisions of adult stem cell populations in skeletal muscle (2013). For this work Chibeza was awarded the Tadien Rideal Prize for outstanding doctoral research in molecular science. After finishing his PhD, Chibeza began his postdoctoral training at the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. In the year that followed, Chibeza was appointed a Research Fellow in Genetics at Homerton College,

University of Cambridge and went on to found a start-up software company called CamBioScience Limited. CamBioScience has built a cloud platform called OBRIZUM® that delivers adaptive online courses, assessment and analytics tools for students and professionals in the life sciences and healthcare sectors.

CamBioScience’s OBRIZUM® platform combines cutting-edge content with custom-built Artificial Intelligence and Augmented Video Reality technology to meet the demands of the rapidly advancing fields of science and technology. The platform is built to overcome the content, cost, and scale challenges of providing skill-based learning, training and development opportunities to a globally distributed workforce or student base.

Giacomo Bastianelli

Giacomo Bastianelli holds a PhD in bioinformatics from the Pasteur Institute in Paris and a M.Sc. in Pharmaceutical Biotechnology from the University of Bologna. Giacomo is an entrepreneur/executive who founded and managed biotech and high-tech

companies (Meiogenix, BliNK Therapeutics, Travellution, Key Neurosciences, Lounjee, SCI-BRAIN). Giacomo has business training from Stanford University (Graduate School of Business) and HEC (Executive Education) in Paris.

David is an investor and entrepreneur, currently with CoinList Capital - the cryptocurrency-focused spin-out from digital startup platform AngelList. Previously, David led international growth at Carta, operations at AngelList, has worked with venture capital investors including 500

Startups and Global from Day One, and founded four companies of his own, including London based micro-consultancy Tech Connect. David was a GAP Summit attendee in 2016, and has a deep interest in biotechnology startups.

84

David Booth

Emilia is a scientist, entrepreneur, writer and speaker. She has been recognized as a leader in biotech and high tech both in her country and internationally thanks to her work in her synthetic biology startup, Kaitek.

After 4 years of writing about global

A chemical engineer entrepreneur, Victor is driven by the potential of technology to accelerate medical research and enable personalised curative treatments. Since founding Desktop Genetics (www.deskgen.com) in 2012, Victor has led the company’s CRISPR genome-editing business development, placing the fast-growing company as a market leader in CRISPR design and analysis solutions. In this time, he has secured over $4M in business and research financing, out-licensed the DESKGEN technology to top pharmaceutical companies, in-licensed novel technology and managed the company's operations, from early R&D through commercialisation of innovative CRISPR products and services for genomics research and next-generation cell therapy.

David is a biomedical research scientist and entrepreneur in medical device innovation and global business development. David is founder of CamStent Ltd, a university spinout, and of Acacia Designs BV, a collaboration with a Mayo Clinic physician that was recently acquired by Senzime AB. Both companies have

biotech in various outlets and seeing the lack of Latin representation in the global scope, she also founded Allbiotech: the first Latin American Biotech network for biotech. She seeks to grow the local ecosystem through scicomm and innovation.

Prior to founding Desktop Genetics, Victor was an entrepreneurial fellow at Boston-based $1bn fund Flagship Ventures, turning cutting edge science into new companies. In his active role as supporter of student entrepreneurship, Victor regularly speaks and mentors aspiring tech and biotech entrepreneurs in schools, universities and competitions including the OneStart challenge and the Dubai100 accelerator.

Emilia Diaz

Victor Dillard

85

Victor holds an MEng in Chemical Engineering from Imperial College London and an MPhil in Bioscience Enterprise from the University of Cambridge. In 2017 he was nominated Entrepreneur of the Year by the MIT Technology Review Innovators Under 35 and was elected Forbes 30 Under 30.

manufacturing facilities and clinical product approved for market; Acacia was recently acquired by Senzime AB. David was preciously an elected Fellow at Medtronic’s Bakken Research Center in Maastricht and Research Director at Physio-Control Corp in Seattle. He leads the Medical Device and Diagnostics course as

David Hampton

Voices of Tomorrow Mentors Senior Associate at the University of Cambridge. His academic background includes an MPhil with distinction also from Cambridge, Management Science studies at Stanford University,

Masters and PhD degrees in Biomedical Signal Processing from Northwestern University, and a Bachelor’s in Physics and Applied Mathematics from Vanderbilt University.

David Holden-White

Experienced Founder with a demonstrated history of working in the biotechnology industry. Skilled in Corporate Development, Patent Law, Biotechnology, Management, and Seed fundraising. Strong professional

with a Master's Degree in Bioscience Enterprise from University of Cambridge, 1st class Masters in Biochemistry from Oxford University and Merit in Intellectual Property Law from Queen Mary University.

Maria Hwa Young Oh

Maria currently heads business development for Australasia and Asia at Fulgent Genetics. She's a co-founder of BioFoundry, a biotech co-working space housed at the Australian Technology Park and a strategic advisor for BuddingTech, a medical cannabis

accelerator program. She was previously an IARU research fellow at Yale Medical School, PhD candidate in molecular genetics at University of Sydney and is currently completing her JD studies.

Max Kelly

Max is VP of Strategy and Innovation for Techstars globally. Techstars is the worldwide network that helps entrepreneurs succeed. Prior to Techstars, Max spent 12 years at Virgin where he was responsible for the strategy of the group and for starting new companies.

His Virgin companies exited for more than $500M for Richard Branson.

Alongside his Virgin commitments, Max also co-founded lastsecondtickets.com which was successfully sold in 2014. He started his career at L’Oreal running the UK’s largest haircare brand – the irony was lost on no one. He was a scholar at Oxford University, where he obtained a First Class Degree in Chemistry.

86

Associate Professor Andreas Hougaard Laustsen heads the Tropical Pharmacology Lab at the Department of Biotechnology and Biomedicine, Technical University of Denmark. He is specialized in antibody discovery, toxinology, antivenom, and neglected tropical diseases. Andreas is an Advisor to the WHO’s Working Group on Snakebite Envenoming, and he is a co-founder of the biotech companies Biosyntia (synthetic biology and metabolic engineering), VenomAb (recombinant antivenoms), Antag Therapeutics (metabolic diseases),

Chromologics (fermented food colors), Bactolife (infectious diseases), and VenomAid Diagnostics (snakebite diagnostics), having raised approx.

USD 8M in total. Andreas is recognized as Denmark’s Coolest Engineer, a Top 6 Academic Entrepreneur under 35 in Europe 2017, and he was on Forbes 30 under 30 list for 2017 and MIT Technology Review’s list of the 35 Top Innovators under 35 in Europe 2017.

Andreas Laustsen

Lab website: http://tropicalpharmacology.com

87

Adina Mangubat is the CEO and co-founder of Spiral Genetics, a leader in population genomics. Spiral Genetics makes software to analyze and compare large populations to enable the discovery of genetic variations important for diseases and conditions. At Spiral Genetics, she leads complex sales to highly technical audiences, drives business development and product vision, and has built a diverse team of highly talented technical and scientific individuals to develop the world’s most advanced bioinformatics technology.

In addition, she is the primary catalyst for creating a transparent, high integrity, and mission-driven culture.

Early in her career, Adina worked with two other high-technology companies wherein her role included team

development, brand development, marketing, channel development and sales for complex technologies. A graduate of the University of Washington, Adina holds a B.S. in Psychology with a focus on Entrepreneurship and was recognized by the Washington Biotechnology and Biomedical Association as one of the 2013 Women to Watch in Life Science. Additionally, she was featured in Forbes 2013 “30 under 30″ for Science and Healthcare. In 2017, Forbes named her as one of the All Star Alumni for the 30 under 30 in Science and Healthcare.

Adina’s passion for world-changing technology, coupled with her adept entrepreneurial focus and clear team development skills have enabled her to bring Spiral’s technology to the forefront of bioinformatics innovation.

Adina Mangubat

Voices of Tomorrow Mentors Urvashi Prasad

Before joining Operation ASHA as a Director, Urvashi led a multi-million dollar health portfolio of the Michael & Susan Dell Foundation in India focused on improving the lives of the urban poor. During her tenure at the foundation, Urvashi catalysed school health programs that reached out to over 15 million children. She also formulated a school health implementation framework in collaboration with the Government and other stakeholders.

Urvashi has worked as a consultant for

the World Health Organisation and with the Partnership for Child Development, Imperial College London. Urvashi is also on the Governing Board of Partnership for TB Care & Control, India’s largest TB network. She is a World Economic Forum Global Shaper. Urvashi completed her Bachelors in Genetics from University of Birmingham followed by an MPhil in Bioscience Enterprise from University of Cambridge and an MSc in Public Health from the London School of Hygiene & Tropical Medicine.

Anya Roy

Anya is a Life-science Investment Manager at IP Group, a global venture capital firm. She began her career at Barclays Capital and transitioned to Goldman Sachs where she was promoted from Analyst to Associate. She has also worked for the European Investment Bank which is the Investment arm of the European Union. She has a Master’s from Cambridge University and was

awarded the Christopher Lowe Carpe Diem Award as well as a scholarship from Christ’s College. Her interests lie in healthcare innovation and medical technology having worked in general medicine within the NHS. She co-founded a women’s health company, Syrona and is an advocate for diversity within entrepreneurship.

Matthew Scholz

Matthew Scholz is Immusoft’s founder and Chief Technology Officer.

His curiosity about how the body attacks invading pathogens and stores the information sparked his idea for Immusoft. He realized that he could modify technology developed by Nobel Laureate David Baltimore to program resting B cells to secrete therapeutic proteins. The modified system is the core of Immusoft’s technology platform, Immune System Programming™. Immusoft, which under Matthew’s leadership is transitioning

from a research biotech to a clinical company, has raised capital from the U.S. National Institutes of Health, Peter Thiel’s Breakout Labs, Founders Fund Science, and prominent private investors, including Tim Draper and the former head of preclinical development at Seattle Genetics. Matthew has a degree in computer science. He is a mentor for the Thiel Fellowship, a program that awards grants to some of the brightest scientific minds in the world under age 20.

88

BSc in Biomedical Sciences, MSc in International Business: I knew early on that I was not cut out to be a researcher, rather combining both science and business somehow.

Beginning my career in consulting focused on pharmaceutical strategy, I later moved into the life science venture capital space working for a Paris-based VC called Kurma Partners. My initial focus was Orphan

disease therapeutics, but then moved onto a Diagnostics/e-health dedicated fund where I worked on 9 earlystage investments. Since September 2017 I freelance, mainly focusing on bringing my strategic experience to early-stage companies with highly operational teams. In addition, I have worked actively with various advisory panels including for the Swedish Innovation Agency.

Simon Turner

Emil Syundyukov is an entrepreneur with a particular interest in medical applications of computer science, embedded systems, and wireless sensor networks. CEO of Koatum - presenting a multi-layered unique hybrid implant coating solution. PhD in Computer Science (Persuasive systems in Healthcare), Researcher in Institute of Electronics and Computer Science, before that held a number of developer roles.

Lead at Start(IT) Educational Foundation, which aims to improve ICT education in Latvia and raise awareness of the potential of digitalization in society

generally. He has also been active in public and educational settings, hosting radio shows and mentoring teachers on the transformative potential of IT.

Emil Syundyukov

Sybil Wong, PhD is Head of Growth & Partnerships for Sparrho, a startup blending expert curation and machine learning to help users from 150+ countries stay on top of the science that matters to them. Prior to joining Sparrho, Sybil managed

the global OneStart biotech and healthcare startup accelerator. Sybil completed her PhD in Biochemistry at the University of Nottingham and Barts Cancer Institute, Queen Mary, University of London.

89

In 2016 he was named among the Forbes 30 under 30 (Science and Medicine), an annual list published by Forbes Magazine recognizing 30 young business and industry figures. GapSummit 2016 participant, "Voices of Tomorrow" challenge finalist.

Linkedin profile: https://www.linkedin. com/in/syundyukov

Sybil Wong

GapSummit 2018 Executive Committee Felix Breyer President PhD Student, University College London / Francis Crick Institute

I am currently a PhD student at University College London, carrying out my research at the Francis Crick Institute. My PhD project, for which I have been awarded a Boehringer Ingelheim Fellowship, focuses on signaling pathways underlying human inflammatory diseases. I have previously graduated

with a First Class Honours degree in Biochemistry from the University of Dundee, Scotland. I have developed a strong passion for biotech over the past years, which is the reason why I attended the GapSummit 2016 as a Leader of Tomorrow.

Daniel Bode Chief Operating Officer PhD Student, University of Cambridge / Stem Cell Institute

I am currently a PhD student at the University of Cambridge. I conduct my research at the Cambridge Stem Cell Institute and mainly focus on characterising molecular mechanisms in subtypes of haematopoietic stem cells.

Before embarking on my PhD project

in Cambridge, I graduated with First Class Honours in Biochemistry from the University of Dundee. I first learned about the remarkable mission and vision of the Global Biotech Revolution at the GapSummit 2016, which I attended as a Leader of Tomorrow.

Karen Duffy LoT Liaison PhD Student, University of Cambridge

Karen received her B.S. in Biological Engineering and M.Eng in Biomedical Engineering from Cornell University.

She then spent several years working in industry in Boston, both big pharma and small biotech. Last year, she moved to Cambridge, U.K. to pursue a

PhD studying synthetic biology at the MRC Laboratory of Molecular Biology.

She was also a delegate of the inaugural 2014 GapSummit, and is excited to continue working with the team in the role of Leaders of Tomorrow Liaison.

Tim Lohoff Marketing Officer PhD Student, University of Cambridge / Stem Cell Institute

I am currently a student on the Wellcome Trust PhD Programme in Stem Cell Biology & Medicine, University of Cambridge. The overall aim of my PhD project is to understand the precise mechanisms orchestrating cell fate commitment in early mammalian development. Previous to that, I have graduated with a First Class Honours

degree in Regenerative Biology and Medicine from the Center for Regenerative Therapies Dresden, Germany.

My basic studies in the field of developmental and stem cell biology motivated me to participate at the Dresden International Summer School on Technology Transfer and Life Science in 2015.

90

Norbert earned his Masters degree in Life Sciences and Technologies from the Swiss Federal Institute of Technology in Lausanne. Prior to that, he graduated with an honors degree in Molecular Bionics Engineering from Pázmány Péter Catholic University in Budapest. Norbert has done research in the fields of structural biology, ubiquitination, computational neuroscience and translational neuroengineering,

and is currently working as a software engineer on a cancer drug research artificial intelligence platform. His longterm vision is to integrate his experience in computer science and biotechnology, working in creating the new emerging industries of the 21st century. Norbert became involved in Global Biotech Revolution as the Information Technology Officer of GapSummit 2018.

Norbert Majubu Information Technology Officer Biotech Programmer, Turbine.AI

I am currently pursuing a Master’s degree in Systems Biology at the University of Cambridge, where I previously graduated with a First Class Honors degree in Natural Sciences.

Living in Cambridge, a global hub for biotechnology, has exposed me to the innovation present in this

sector. Having previously attended GapSummit 2017 as a delegate, my vision for this year’s edition is to bring together the most diverse, innovative and motivated leaders of tomorrow to catalyse inspiring discussions and to encourage the generation of revolutionary ideas.

Mie Monti Marketing Officer Masters Student, University of Cambridge

I am currently a Wellcome Trust PhD Student and previously graduated in Biosciences from the Ecole Normale Superieure of Lyon with high honors.

I learned how to conduct advanced research worldwide throughout several internships in developmental biology, epigenetic and regenerative medicine. Passionate about

translating research, I undertook an engineering diploma in biotechnology at the Ecole des Mines of Paris where I had the opportunity to intern as an analyst in a VC company focused on life sciences. My vision for the VoT is to bring together the most passionate minds to solve the future challenge of the biotech ecosystem.

Marion Perrin Voices of Tomorrow Coordinator PhD Student, University of Cambridge / Stem Cell Institute

I am currently a MPhil Student at the University of Cambridge studying Bioscience Enterprise. My real interest lies in taking new technologies into market. The MPhil focuses on expanding knowledge of healthcare economics and business practices regarding biomedical technology development and marketing. I have previously graduated with a First Class Honours degree

in Biochemistry from the University of Bristol. Attending Cambridge University Entrepreneur Society and Young Entrepreneur of the Year Workshops to enhance pitching skills, business plan writing I boosted my interest in entrepreneurship. As part of the VoT I want to facilitate the creation of innovative ideas to solve the biggest challenges in the biotech ecosystem.

Emily Wyatt Voices of Tomorrow Liaison MPhil Student, University of Cambridge

91

GBR Executive Committee Anna Gould President

Anna has led Global Biotech Revolution since June 2017. She became involved in GBR as a Leader of Tomorrow at the first GapSummit in 2014, and then led the organisation of the next GapSummit in 2016 as Vice President, and has been a member of the GBR executive team ever since. She holds a Masters in Bioscience Enterprise

from the University of Cambridge, as well as chemical and process engineering degrees from ETH Zurich and the University of New South Wales.

Since September 2016 she has been working in strategy consulting at Merck KGaA, based in Germany, Boston and London.

Christian Guyader Co-Founder & Vice President

Christian co-founded Global Biotech Revolution and as Vice President currently focuses on finance, strategy and advising the GapSummit teams.

Christian is a management consultant in the London Office of The Boston Consulting Group where he mostly

advises pharmaceutical companies and private equity firms. Christian holds a PhD, an MEng and a BA in Chemical Engineering, all from the University of Cambridge. His PhD work focused on the design of non-viral vectors for gene therapy.

Carthur Wan Vice President

Carthur has been part of Global Biotech Revolution since 2012 as part of the inaugural GapSummit organising team. Prior to GBR he helped to build Chiasma, a New Zealand non-profit that bridges the industry-academia divide. He is a currently a Consultant

at CIS, a Melbourne-based boutique advisory firm that primarily works with Australian universities and research institutes. Carthur holds a PhD in neuroscience (The University of Auckland) and a Master of Management (Melbourne Business School).

Ipshita Mandal Co-Founder

Ipshita came up with the idea behind a "GapSummit" and registered it under Global Biotech Revolution in February 2012. She was President of GBR until June 2017 and currently focuses on long-term strategy projects for the organisation. After running a biotech drug discovery start-up in Cambridge,

Ipshita joined McKinsey & Company working on digitization across sectors in India. Ipshita holds a PhD in Chemical Engineering from University of Cambridge and BTech from University of Auckland and National University of Singapore.

92

Frieder joined Global Biotech Revolution in 2012 and helped to bring the very first GapSummit in 2014 to life as COO. Today he supports the development of the organisation in the role of GBR Strategy & IT Director. After completing his PhD in Biotechnology at the University of Cambridge he

joined Limbach Gruppe SE, a leading German laboratory diagnostics company. Within the business development department he is working on business models that will bring diagnostic innovation and technology to the public health care market.

Frieder Haenisch Strategy & IT Director

Janice joined GBR in 2012 as Sponsorship Director for GapSummit 2014, and in 2013 she took the role to manage GBR Brand and Marketing. Janice is a technology commercialisation consultant at PlaTCOM Ventures, Malaysia.

She identifies innovative business opportunities, facilitates technology transfer, and advises fledgling

SMEs, innovators and entrepreneurs.

Prior joining PlaTCOM, Janice was a Product Development Manager at Horizon Discovery, UK. Janice holds a PhD in Biophysical Chemistry from University of Cambridge and a Master of Science in cancer epigenetics from Monash University.

Janice Ng Business Development Manager

Norbert earned his Masters degree in Life Sciences and Technologies from the Swiss Federal Institute of Technology in Lausanne. Prior to that, he graduated with an honors degree in Molecular Bionics Engineering from Pázmány Péter Catholic University in Budapest. Norbert has done research in the fields of structural biology, ubiquitination, computational neuroscience and translational neuroengineering,

and is currently working as a software engineer on a cancer drug research artificial intelligence platform. His longterm vision is to integrate his experience in computer science and biotechnology, working in creating the new emerging industries of the 21st century. Norbert became involved in Global Biotech Revolution as the Information Technology Officer of GapSummit 2018.

Norbert Majubu IT Manager

Toryn Dalton read Natural Sciences at the University of Cambridge, UK, where he was also President of Trinity College Science Society. He then completed the GlaxoSmithKline Future Leaders Programme, gaining experience in drug Discovery, Development and

Manufacturing. After a short research stay at the University of Auckland, NZ, he recently began his doctoral studies in organic chemistry at the University of Münster, DE. His interests include novel antibiotics, neurodegenerative diseases and sustainable chemistry.

Toryn Dalton Data Insights Manager

93

GBR Executive Committee Alisa Molotova Alumni Engagement Manager

Alisa first joined the GBR family when she was a LoT at the inaugural GapSummit in 2014, whilst studying her undergraduate degree at the University of Glasgow. She later joined the University of Cambridge for her

PhD in Stem Cell Neurosciences and was the COO of the 2016 GapSummit.

Later, she moved on to an executive role on the current GBR committee working with GBR alumni and the GapSummit 2018 team.

Lillian Kuan Digital Content Manager

Lillian was a Leader of Tomorrow at the GapSummit 2014, and has a Master of Commercialisation and Entrepreneurship, and a Master of Science in Biomedical Science from the University of Auckland with research focused on breast cancer. Currently she is the Digital Content Manager at Global Biotech Revolution and looks after its

social media channels. By day she’s an Editorial Coordinator at Dove Medical Press, an open access biomedical science journal publisher recently acquired by Taylor & Francis. She also sits on the Alumni Advisory Board for Chiasma, a student organisation bridging science and business in New Zealand.

Harsh Vaidya Voices of Tomorrow Manager

Harsh has a strong interest in helping innovative ideas transform into products and services. He was amongst the first batch of Leaders of Tomorrow in 2014 and has several years of experience in organising workshops and events that drive innovation towards

market.

Harsh currently works as a scientist at Cogen Therapeutics, a Flagship Pioneering startup in Cambridge, MA. He has a M.Sc. in Bioinformatics and a Ph.D. in Stem Cell Biology from the University of Edinburgh, UK.

Hugh Allison Community Manager

Hugh is a PhD candidate in physics at UNSW Sydney, where he works to develop advanced methods of biomolecular imaging.

He first became interested in biotechnology as an undergraduate in chemical

engineering at UC Berkeley, leading to his involvement with GBR. He aspires towards a position in research and development in the emerging industry of biopharmaceuticals.

94

Acknowledgements We would like to express special thanks to the GapSummit 2018 Advisory Board: Sir Gregory Winter, Professor Chris Lowe, Professor Christopher Dobson, Dr Jane Osbourn and Dr Menelas Pangalos.

The GapSummit 2018 would also not have been possible without the insights and fantastic support of our speakers, sponsors and VoT mentors.

We would like to thank our hosts St John’s College & Trinity College as well as the following organisations for their support: Johnson & Johnson 96

GSK AstraZeneca / MedImmune Sanofi Bayer Merck KGaA Novo Nordisk McKinsey & Company

We are also grateful for the travel grant support from Sparrho.

A final thank you goes to the Global Biotech Revolution Executive Team who were always on hand to guide and support us.

GapSummit 2018 is sponsored by Platinum sponsors

Gold sponsors

97

Silver sponsor

Bronze sponsor

Knowledge partner

Hosts

www.jnjinnovation.com | @jnjinnovation | #championsofscience

Fueling Champions of Science For better health For more cures For a world without disease For a brighter future For a longer, healthier, happier life For us, our children & grandchildren‌ science needs champions!

Š Johnson & Johnson Innovation, LLC 2018

We have more than 100,000 employees working towards 1 common purpose; access to healthcare for all. How will you help us achieve it?

To challenge. To change.

Find a career with purpose at gsk.com/careers

Najoua Senior Business Development Manager Belgium

GAP Summit AstraZeneca is a global, innovation-driven biopharmaceutical company that spans discovery, development, manufacturing, distribution and worldwide commercialisation of new medicines.

Our research is focused on three main therapy areas of Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Our support for science in Cambridge builds on the local legacy of Cambridge Antibody Technology (CAT) which was acquired by AstraZeneca and integrated with MedImmune in 2007.

Cambridge is the heart of UK life sciences and offers us the perfect location for the hundreds of research collaborations and business partnerships to help drive our innovation. We look forward to meeting you and we hope you find some great learning opportunities in our city this week.

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health.

We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering.

We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Proud Gold Sponsor

Find out more about us at our Workshop on digital health, Tuesday, 17th April

FOLLOW US sanofi.com/en/careers

ALWAYS CURIOUS

ITHE NEXT AGINE 350 YEARS Curiosity is in our DNA. Since 1668, we‘ve explored uncharted territory in science and technology. We can only imagine what the next 350 years have in store.

Can you?

Discover more: merckgroup.com/350

ambition welcomed For more information visit novonordisk.com

Knowledge partner of the GapSummit 2018 For more of our latest thinking, visit McKinsey.com or download the McKinsey Insights app from the Apple App Store or Google Play

Insights for you

Synthetic biology What do you get when you combine genetic engineering with big data analytics? A new technology for disruptive innovation

Pursuing breakthroughs in cancer-drug development Innovating at the speed of the 21st century in pharmaceuticals

Venue Details

107

GapSummit Venue

Gala Dinner (16th April)

We are delighted to be holding the GapSummit at the Old Divinity School of St John’s College, Cambridge.

Proceedings including speaker registration, speeches and panel sessions will be taking place here. The St. John’s Old Divinity School is situated opposite the Great Gate to St. John’s College.

All speakers and Leaders of Tomorrow are invited to a Grand Formal Dinner at Trinity College, located on Trinity Street, a short walk from the Old Divinity School (see map on p108).

Dress code: business wear St. John’s Divinity School St. John’s College St. John’s Street Cambridge CB2 1TP (see map on p108)

6:30 pm - 7:15 pm: Pre-dinner drinks in the Master’s Lodge 7:30pm - 10:00 pm: Three-course formal dinner in Great Hall with keynote speaker Baroness Manningham-Buller, Chair, Wellcome Trust Dress code: business wear Trinity College Cambridge CB2 1TQ

Networking Evening (17th April) All speakers and Leaders of Tomorrow are invited to a Networking Evening at the Museum for Archaeology and Anthropology. We encourage vivid interaction between speakers, delegates, sponsor representatives and GapSummit Alumni to innovate, connect and challenge. Drinks and a full warm buffet dinner will be served.

Dress code: business wear Downing St Cambridge CB2 3DZ

Map

s is how it will look in view-only mode. Dismiss

Key t. John’s Divinity School S Main GapSummit venue rinity College T 16th April dinner venue ambridge Union Society C Workshops venue useum of Archaeology M & Anthropology (MAA) Sidney Sussex College Pembroke College 108

Accommodation Accommodation for Leaders of Tomorrow Pembroke College Pembroke College, Cambridge CB2 1RF Sidney Sussex College Sidney Street, Cambridge CB2 3HU Please see next page for additional directions

Accommodation directions Accommodation for Leaders of Tomorrow Pembroke College Pembroke College, Cambridge CB2 1RF (see map on p108).

Arriving by Train: Walking to both Colleges takes ~35 min. From the Rail Station cross the roundabout heading northwest and take Station Rd. Continue until Hills Rd; at the junction turn right.

Continue until reaching Lensfield Rd, turn left onto Lensfield Rd. At the roundabout turn right to take Trumpington St.

Continue until reaching Pembroke College on your right-hand side, opposite the Cambridge Open Church at the corner to Mill Ln.

take St Andrews St. Cross the street and walk until Downing St junction (at the opposite corner you'll see a big store called John Lewis) and turn left.

Arriving by coach:

Downing St changes name to Pembroke St, keep walking until you reach Trumpington St and turn left to see the main entrance to Pembroke College on your left-hand side.

Coaches stop at the Parkside Station, within walking distance of the Colleges taking about 20 min.

Take Park Terrace street (towards northwest), at the junction turn left.

Then at the T junction turn right to

Please report to the Porter’s Lodge for keys and directions to your room.

The main entrance to Sidney Sussex College is situated opposite the entrance to Sainsbury’s supermarket (large wooden door)

until you see Lloyds bank

Sidney Sussex College Sidney St, Cambridge CB2 3HU (see map on p108).

Arriving by Train: Walking to both Colleges takes ~35 min. From the Rail Station cross the roundabout heading northwest and take Station Rd. Continue until Hills Rd; at the junction continue straight onto Regent St. Regent St. merges into St Andrew’s St; continue until you see Lloyds bank Follow Sidney St. on the left-hand side until reaching Sainsbury’s supermarket

Arriving by coach: Coaches stop at the Parkside Station, within walking distance of the Colleges taking about 20 min.

Take Park Terrace street (towards northwest), at the junction turn right onto St Andrew’s St. and continue

Follow Sidney St. on the left-hand side until reaching Sainsbury’s supermarket The main entrance to Sidney Sussex College is situated opposite the entrance to Sainsbury’s supermarket (large wooden door) Please report to the Porter’s Lodge for keys and directions to your room.

109

Other Information

110

ŠChris Williamson

Catering We are delighted to offer full coverage of all meals, drinks and refreshments throughout the main conference days from the 16th to 18th April. This includes meals on all three nights – the Gala Dinner (16th April), the Networking Evening (17th April) and the closing dinner (18th April). We will also provide light refreshments during the ice breaker events on Day 0, Sunday 15th April, but

are unfortunately unable to provide full warm dinner on the 15th April. Similarly, delegates that wish to join social activities on the 19th April are expected to cover their own lunch costs.

Preparing for GapSummit There is no formal preparation required for the summit. However, do come along having prepared your own

thoughts, ideas and questions on each of the gaps in order to get the most out of the experience.

Formal Dress code required Please note that the dress code for the GapSummit is business wear. For the optional social activities on Sunday 15th April and Thursday 19th April, casual clothes will be appropriate.

Workshops

Directions to Cambridge

The workshops will be held at the historic Cambridge Union building, a short walk from the main venue (see map on p108), and St John’s College Old Divinity School (main venue).

The City of Cambridge is located in the East of England, 50 miles north of London. It is well served by road and rail links, and is within easy distance of the major London airports.

The Cambridge Union Society, 9A Bridge Street, Cambridge CB2 1UB

EU flights London Stansted Airport is just 30 miles from Cambridge. An hourly 35 min direct train service runs from Stansted to the City. It is also possible to fly directly into Cambridge by using Cambridge International Airport.

However, a very limited amount of flights are available to and from Cambridge International Airport.

We recommend to use London Stansted Airport.

St. John’s Divinity School, St. John’s College, St. John’s Street Cambridge CB2 1TP 4:45 pm - 5:30 pm Workshop Session 1 5:45 pm - 6:30 pm Workshop Session 2

©Chris Williamson

Intercontinental flights London Heathrow Airport is situated 2h from Cambridge. It is possible to take a train into London King’s Cross and then take another train to Cambridge.

Train There are regular services to Cambridge from London King’s Cross and London Liverpool Street stations. The fastest trains leave from London King’s Cross every half hour and take 50 min.

Car Cambridge is an hour’s drive from London, depending on traffic. Please do note that the centre of Cambridge is mostly free of private cars, especially around the conference venue.

Parking at the GapSummit venue is not available.

111

Cambridge Sights

112

Punting The River Cam runs through the heart of Cambridge enabling you to enjoy fantastic views of the world-famous Cambridge College ‘Backs’ from the comfort of a traditional Cambridge Punt. Tours time is about 45-minutes.

Price around £14.00.

Colleges A guided walking tour of the University and the Colleges is the best way to see Cambridge. Your tour could include the beautiful King's College and Chapel, the finest building of its type in Europe, the intimate Queens' College with its wonderful sun and moon dial, Pembroke College and Emmanuel College with their peaceful gardens and chapels designed by Sir Christopher Wren.

Cambridge University Botanic Gardens Discover plants from all over the world in 40 acres of beautiful gardens and glasshouses. Opens daily at 10am.

Admission fee £4.50 (£3.95 students with a recognised identification card.)

Cambridge University Fitzwilliam museum The Fitzwilliam Museum is the art and antiquities museum of the University of Cambridge, located on Trumpington Street opposite Fitzwilliam Street in central Cambridge. Few museums in the world contain on a single site collections of such variety and depth.

Admission is free.

The Eagle When the university's Cavendish Laboratory was still at its old site at nearby Free School Lane, the Eagle pub was a popular lunch destination for staff working there. It became a part of history when Francis Crick interrupted patrons' lunch on 28th February 1953 to announce that he and James Watson had "discovered the secret of life" after they had come up with their proposal for the structure of DNA. The anecdote is related in Watson's book The Double Helix and commemorated on a blue plaque next to the entrance. Today the pub serves a special ale to commemorate the discovery, dubbed “Eagle's DNA”.

Programme Overview Day 0 — 15th April

Leaders of Tomorrow Welcome Day

14:00

Check-in at Pembroke or Sidney Sussex College from 12pm

15:30 – 16:15

Registration at Old Divinity School

16:15 – 16:30

Introductions

16:30 – 18:00

Welcome Sessions

18:00 – 19:00

Networking Drinks

113

Day 1 — 16th April 08:00 – 08:45

Registration and Breakfast

08:45 – 09:00

Welcome

09:00 – 10:00

Opening Keynote - Dr Trevor Mundel

10:00 – 10:15

Personalised Medicine Gap – Anu Acharya

10:15 ­- 10:45

Refreshments

10:45 – 12:00

Personalised Medicine Gap - Panel Discussion

12:00 – 13:00

Lunch

13:00 – 13:15

Digital Health and its Impact on the Pharma Industry - Dr Ameet Nathwani

13:15 – 14:30

Digital Health Gap - Panel Discussion

Programme Overview 14:30 – 15:00

Refreshments

15:00 – 15:20

Exploring fundamental unknowns that prevent us from using our devices to navigate between disease and health - Dr Stephen Friend

15:20 - 16:20

Keynote - Dr Göran Ando

16:20 - 16:50

Refreshments

16:50 – 18:00

Road from Academia to Industry Gap - Panel Discussion

18:00 – 18:30

Intermission

18:30 – 19:30

Drinks Reception at the Trinity College Master’s Lodge

19:30 – 22:00

Gala Dinner in the Great Hall, Trinity College

114

Day 2 — 17th April 08:00 – 08:45

Breakfast

08:45 – 09:00

Science, Ideology and daily life: The case of innovation for Tropical Crops Prof Baron Marc Van Montagu

09:00 – 10:00

Agritech Gap - Panel Discussion

10:00 - 10:45

Keynote - Mr Fabrizio Hochschild

10:45 – 11:15

Refreshments

11:15 – 12:15

Drug Affordability Gap - Panel Discussion

12:15 – 12:30

Emerging opportunities for the biotech industry - Dr William A Haseltine

12:30 – 13:30

Lunch

13:30 – 14:30

Keynote - Innovate with Impact

14:30 – 15:00

Addressing the Innovation Challenge - Dr Kemal Malik

15:00 - 15:30

Refreshments

15:30 – 16:30

R&D Productivity Gap - Panel Discussion

16:30 – 16:45

Walk to Workshop venue

16:45 – 18:30

Workshop sessions

18:30 – 19:30

Intermission

19:30 – 22:00

Networking event at the Museum of Archaeology and Anthropology, Cambridge

Day 3 — 18th April 08:00 – 08:45

Breakfast

08:45 – 09:45

Keynote - Kiran Mazumdar-Shaw

09:45 - 10:15

Life as a CEO – Interview with Dr David Pyott

10:15 – 10:45

Refreshments

10:45 – 12:00

Funding Gap - Panel Discussion

12:00 – 13:00

Lunch

115

Programme Overview

116

13:00 – 15:00

Voices of Tomorrow Competition Finals

15:00 – 15:30

Refreshments

15:30 – 16:30

Young Entrepreneurs Gap - Panel Discussion

16:30 – 16:45

Wielding the power of the small – enzymes and microbes – to tackle the challenges laid out by the Sustainable Development Goals - Dr Claus Stig Pedersen

16:45 – 17:00

Refreshments

17:00 – 18:00

Sustainability & White Biotech Gap - Panel Discussion

18:00 – 18:15

Voices of Tomorrow Competition Winner Announcement

18:15 – 18:30

Closing Speech and Concluding Remarks

18:30 - 19:30

Celebratory Drinks Reception

19:30 – open

Social Evening

Day 4 — 19th April

Social Activities And Departures

By 09:30am

Vacate room

09:00 – 16:00

Store luggage at Old Divinity School

12:00 – 14:00

Punting

14:00 – 15:30

Lunch

16:00

Final Departure

gapsummit.com globalbiotechrevolution.com